<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia - Ng, SM - 2020 | Cochrane Library</title> <meta content="Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia - Ng, SM - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012517.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia - Ng, SM - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012517.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012517.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia" name="citation_title"/> <meta content="Sze May Ng" name="citation_author"/> <meta content="ngszemay@yahoo.com" name="citation_author_email"/> <meta content="Karolina M Stepien" name="citation_author"/> <meta content="Salford Royal NHS Foundation Trust" name="citation_author_institution"/> <meta content="Ashma Krishan" name="citation_author"/> <meta content="University of Liverpool, Alder Hey Children's NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012517.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/03/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012517.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012517.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012517.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Hyperplasia, Congenital [*drug therapy]; Dexamethasone; Glucocorticoids [*therapeutic use]; Prednisolone; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012517.pub2&amp;doi=10.1002/14651858.CD012517.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012517\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012517\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","ko","fr","ms","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012517.pub2",title:"Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia",firstPublishedDate:"Mar 19, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012517.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012517.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012517.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012517.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012517.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012517.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012517.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012517.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012517.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012517.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4945 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012517.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-sec-0114"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-sec-0108"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/appendices#CD012517-sec-0119"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/table_n/CD012517StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/table_n/CD012517StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information#CD012517-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sze May Ng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information#CD012517-cr-0003">Karolina M Stepien</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information#CD012517-cr-0004">Ashma Krishan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information/en#CD012517-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 March 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012517.pub2">https://doi.org/10.1002/14651858.CD012517.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012517-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012517-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012517-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012517-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012517-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012517-abs-0007">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012517-abs-0001" lang="en"> <section id="CD012517-sec-0001"> <h3 class="title" id="CD012517-sec-0001">Background</h3> <p>Congenital adrenal hyperplasia (CAH) is an autosomal recessive condition which leads to glucocorticoid deficiency and is the most common cause of adrenal insufficiency in children. In over 90% of cases, 21‐hydroxylase enzyme deficiency is found which is caused by mutations in the 21‐hydroxylase gene. Managing individuals with CAH due to 21‐hydroxylase deficiency involves replacing glucocorticoids with oral glucocorticoids (including prednisolone and hydrocortisone), suppressing adrenocorticotrophic hormones and replacing mineralocorticoids to prevent salt wasting. During childhood, the main aims of treatment are to prevent adrenal crises and to achieve normal stature, optimal adult height and to undergo normal puberty. In adults, treatment aims to prevent adrenal crises, ensure normal fertility and to avoid the long‐term consequences of glucocorticoid use. Current glucocorticoid treatment regimens can not optimally replicate the normal physiological cortisol level and over‐treatment or under‐treatment is often reported. </p> </section> <section id="CD012517-sec-0002"> <h3 class="title" id="CD012517-sec-0002">Objectives</h3> <p>To compare and determine the efficacy and safety of different glucocorticoid replacement regimens in the treatment of CAH due to 21‐hydroxylase deficiency in children and adults. </p> </section> <section id="CD012517-sec-0003"> <h3 class="title" id="CD012517-sec-0003">Search methods</h3> <p>We searched the Cochrane Inborn Errors of Metabolism Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles and reviews, and trial registries (ClinicalTrials.gov and WHO ICTRP). </p> <p>Date of last search of trials register: 24 June 2019.</p> </section> <section id="CD012517-sec-0004"> <h3 class="title" id="CD012517-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) or quasi‐RCTs comparing different glucocorticoid replacement regimens for treating CAH due to 21‐hydroxylase deficiency in children and adults. </p> </section> <section id="CD012517-sec-0005"> <h3 class="title" id="CD012517-sec-0005">Data collection and analysis</h3> <p>The authors independently extracted and analysed the data from different interventions. They undertook the comparisons separately and used GRADE to assess the quality of the evidence. </p> </section> <section id="CD012517-sec-0006"> <h3 class="title" id="CD012517-sec-0006">Main results</h3> <p>Searches identified 1729 records with 43 records subject to further examination. After screening, we included five RCTs (six references) with a total of 101 participants and identified a further six ongoing RCTs. The number of participants in each trial varied from six to 44, with participants' ages ranging from 3.6 months to 21 years. Four trials were of cross‐over design and one was of parallel design. Duration of treatment ranged from two weeks to six months per treatment arm with an overall follow‐up between six and 12 months for all trials. Overall, we judged the quality of the trials to be at moderate to high risk of bias; with lack of methodological detail leading to unclear or high risk of bias judgements across many of the domains. </p> <p>All trials employed an oral glucocorticoid replacement therapy, but with different daily schedules and dose levels. Three trials compared different dose schedules of hydrocortisone (HC), one three‐arm trial compared HC to prednisolone (PD) and dexamethasone (DXA) and one trial compared HC with fludrocortisone to PD with fludrocortisone. Due to the heterogeneity of the trials and the limited amount of evidence, we were unable to perform any meta‐analyses. </p> <p>No trials reported on quality of life, prevention of adrenal crisis, presence of osteopenia, presence of testicular or ovarian adrenal rest tumours, subfertility or final adult height. </p> <p>Five trials (101 participants) reported androgen normalisation but using different measurements (very low‐quality evidence for all measurements). Five trials reported 17 hydroxyprogesterone (17 OHP) levels, four trials reported androstenedione, three trials reported testosterone and one trial reported dehydroepiandrosterone sulphate (DHEAS). After four weeks, results from one trial (15 participants) showed a high morning dose of HC or a high evening dose made little or no difference in 17 OHP, testosterone, androstenedione and DHEAS. One trial (27 participants) found that HC and DXA treatment suppressed 17 OHP and androstenedione more than PD treatment after six weeks and a further trial (eight participants) reported no difference in 17 OHP between the five different dosing schedules of HC at between four and six weeks. One trial (44 participants) comparing HC and PD found no differences in the values of 17 OHP, androstenedione and testosterone at one year. One trial (26 participants) of HC versus HC plus fludrocortisone found that at six months 17 OHP and androstenedione levels were more suppressed on HC alone, but there were no differences noted in testosterone levels. </p> <p>While no trials reported on absolute final adult height, we reported some surrogate markers. Three trials reported on growth and bone maturation and two trials reported on height velocity. One trial found height velocity was reduced at six months in 26 participants given once daily HC 25 mg/m²/day compared to once daily HC 15 mg/m²/day (both groups also received fludrocortisone 0.1 mg/day), but as the quality of the evidence was very low we are unsure whether the variation in HC dose caused the difference. There were no differences noted in growth hormone or IGF1 levels. The results from another trial (44 participants) indicate no difference in growth velocity between HC and PD at one year (very low‐quality evidence), but this trial did report that once daily PD treatment may lead to better control of bone maturation compared to HC in prepubertal children and that the absolute change in bone age/chronological age ratio was higher in the HC group compared to the PD group. </p> </section> <section id="CD012517-sec-0007"> <h3 class="title" id="CD012517-sec-0007">Authors' conclusions</h3> <p>There are currently limited trials comparing the efficacy and safety of different glucocorticoid replacement regimens for treating 21‐hydroxylase deficiency CAH in children and adults and we were unable to draw any firm conclusions based on the evidence that was presented in the included trials. </p> <p>No trials included long‐term outcomes such as quality of life, prevention of adrenal crisis, presence of osteopenia, presence of testicular or ovarian adrenal rest tumours, subfertility and final adult height. There were no trials examining a modified‐release formulation of HC or use of 24‐hour circadian continuous subcutaneous infusion of hydrocortisone. As a consequence, uncertainty remains about the most effective form of glucocorticoid replacement therapy in CAH for children and adults. </p> <p>Future trials should include both children and adults with CAH. A longer duration of follow‐up is required to monitor biochemical and clinical outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012517-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012517-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012517-abs-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012517-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012517-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012517-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012517-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012517-abs-0011">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012517-abs-0003" lang="en"> <h3>Glucocorticoid replacement regimens in the treatment of 21‐hydroxylase deficiency congenital adrenal hyperplasia </h3> <p><b>Review question</b> </p> <p>Steroid replacement therapy is used for treating congenital adrenal hyperplasia (CAH) due to 21‐hydroxylase deficiency in children and adults; we looked at the evidence for how well different regimens work and how safe they are. </p> <p><b>Background</b> </p> <p>CAH is a genetic disorder of the adrenal glands that affects the body's general health, growth, and development. Adrenal glands sit above the kidneys and are responsible for making the hormones cortisol and aldosterone. Cortisol helps to regulate blood sugar and blood pressure; and aldosterone is needed to control the salt concentration in the blood. The most common form of CAH is 21‐hydroxylase deficiency (more than 90% of cases). In a child with this type of CAH, the adrenal glands can not make enough cortisol and aldosterone. The glands overwork trying to make these hormones and end up making too many androgens (steroid hormones which regulate the development and maintenance of male characteristics in a person). Steroid medicines similar to cortisol are used to replace cortisol, and fludrocortisone (hormones that are similar to aldosterone) are the usual treatment for CAH due to 21‐hydroxylase deficiency. </p> <p>There are many different schedules and formulations of steroid replacement therapies, e.g. daily, twice‐daily, three‐times daily, more than three‐times daily medications, modified‐release formulation of hydrocortisone or using a 24‐hour circadian continuous infusion of hydrocortisone under the skin. We wanted to know which is more effective in treating 21‐hydroxylase deficiency CAH in children and adults. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 24 June 2019.</p> <p><b>Trial characteristics</b> </p> <p>The review included five trials (six references) comparing different steroid replacement regimens in 101 people with 21‐hydroxylase deficiency CAH. The number of people in each trial varied from six to 44 and they ranged in age from 3.6 months to 21 years. We also found six studies that are still ongoing. </p> <p><b>Key results</b> </p> <p>All trials used an oral therapy, but with different daily schedules and dose levels of steroids. Three trials compared different dose schedules of hydrocortisone, one trial compared hydrocortisone to prednisolone and dexamethasone and one trial compared hydrocortisone with fludrocortisone to prednisolone with fludrocortisone. We found no trials using a modified‐release formulation of hydrocortisone or a continuous 24‐hour delivery under the skin of hydrocortisone. </p> <p>Five trials reported androgen normalisation but using different measurements; none of these results showed any consistent and real difference between therapies. In one trial (26 participants) participants taking a higher dose of hydrocortisone reported a higher growth rate, but we are not sure whether this was directly due to the treatment. In a second trial (44 participants) comparing hydrocortisone to prednisolone we are unsure whether the therapies affect growth rate (due to the very low quality of the evidence). </p> <p>No trials included long‐term outcomes for quality of life, preventing an adrenal crisis, presence of bone fragility, presence of testicular or ovarian adrenal rest tumours, difficulty in conceiving and final adult height. </p> <p><b>Quality of the evidence</b> </p> <p>Many trials had a high or unclear overall risk of bias. There were problems with the quality of the evidence, which was judged to be very low for all outcomes we considered across all the trials. This was because the trials were only small and if they compared a second treatment after the first, they did not leave enough time for the effects of the first treatment to clear. Also, people taking part had previously been treated with different glucocorticoids. </p> <p><b>Conclusions</b> </p> <p>There is not enough evidence to show which steroid replacement treatment schedule results in better outcomes or which is the most effective form of steroid replacement therapy in CAH for adults and children. Large, well‐designed trials are needed to assess the effectiveness and safety of different steroid replacement therapies for treating 21‐hydroxylase deficiency CAH in children and adults. A longer duration of follow‐up is needed to monitor biochemical and clinical outcomes. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012517-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012517-sec-0114"></div> <h3 class="title" id="CD012517-sec-0115">Implications for practice</h3> <section id="CD012517-sec-0115"> <p>The goal of glucocorticoid therapy in congenital adrenal hyperplasia (CAH) is to replace deficient cortisol and prevent the consequences of androgen excess whilst avoiding glucocorticoid over‐treatment. There are limited trials to date which compare the efficacy and safety of different glucocorticoid replacement regimens for treating of 21‐hydroxylase deficiency CAH in children and adults and no evidence to date of which regimen provides optimal outcomes. There were no trials on the modified‐release formulation of hydrocortisone or on the use of 24‐hour circadian continuous subcutaneous infusion of hydrocortisone. No common intervention characteristics for success were apparent among the trials included in this review. </p> <p>The choice of a glucocorticoid regimen needs to be informed by an understanding of the adverse consequences and benefits of different regimens in individuals at different ages and stages of disease. We were unable to draw any firm conclusions based on the evidence that was reported in any of the included trials. It was unfortunate that no trials included long‐term outcomes such as quality of life, prevention of adrenal crisis, presence of osteopenia, presence of testicular or ovarian adrenal rest tumours, subfertility and final adult height. As a consequence, uncertainty remains about the most effective form of glucocorticoid replacement therapy for treating CAH for adults and children. </p> </section> <h3 class="title" id="CD012517-sec-0116">Implications for research</h3> <section id="CD012517-sec-0116"> <p>This systematic review has identified the need for well‐designed, adequately‐powered, multi‐centred randomised controlled trials (RCTs) to assess the efficacy and safety of different glucocorticoid replacement regimens for treating 21‐hydroxylase deficiency CAH in children and adults. RCTs should be carried out over a longer duration (more than 10 years) to monitor biochemical and clinical outcomes and to provide further information on the long‐term effects on quality of life, final adult height, androgen normalisation, prevention of adrenal crisis, osteopenia, subfertility and presence of testicular or ovarian adrenal rest tumours. It is recognised that such long‐term RCTs are likely to be difficult to achieve due to either recruiting sufficient participants to allow for adequate power or due to maintaining follow‐up of participants until adult height is achieved. </p> <p>It should be noted that while one trial reported differences in some growth outcomes, it did not report any differences in growth hormone or IGF1 levels, which indicates that laboratory markers are unreliable and that clinical follow‐up is the most efficient way to evaluate the adequacy of hydrocortisone replacement. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012517-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012517-sec-0036"></div> <div class="table" id="CD012517-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose for treating CAH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HC (13.5 mg/m²/day to 15.5 mg/m²/day) high morning dose compared with high evening dose for treating CAH</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CAH </p> <p><b>Settings</b>: outpatients, tertiary centre </p> <p><b>Intervention</b>: HC (13.5 mg/m²/day to 15.5 mg/m²/day): 50% daily dose in the morning followed by 25% at noon and 25% in the evening </p> <p><b>Comparison</b>: HC (13.5 mg/m²/day to 15.5 mg/m²/day): 25% daily dose in the morning and 25% at noon followed by 50% in the evening </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>High evening dose</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>High morning dose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androgen normalisation</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>Results for 17 OHP are presented as medians (IQR); 44 (16 to 116) for the high morning dose compared to 33 (15 to 76) for the high evening dose. </p> <p><b>Androstenedione (nmol/L)</b> </p> <p>Results for androstenedione are presented as medians (IQR); 1.80 (1.0 to 3.0) for the high morning dose compared to 1.90 (1.20 to 6.50) for the high evening dose. </p> <p><b>Testosterone (nmol/L)</b> </p> <p>Results for testosterone are presented as medians (IQR); 0.70 (0.30 to 2.30) for the high morning dose compared to 1.1 (0.60 to 2.70) for the high evening dose. </p> <p><b>DHEAS (nmol/L)</b> </p> <p>Results for DHEAS are presented as medians (IQR); 0.20 (0.20 to 0.60) for the high morning dose compared to 0.40 (0.20 to 0.70) for the high evening dose. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevention of adrenal crisis</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of osteopenia</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of testicular or ovarian adrenal rest tumours</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subfertility</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Final adult height</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>17 OHP</b> : 17‐hydroxyprogesterone; <b>CAH</b> : congenital adrenal hyperplasia; <b>CI</b> : confidence interval; <b>DHEAS</b> : dehydroepiandrosterone sulphate; <b>HC</b> : hydrocortisone; <b>IQR</b> : interquartile range; <b>NA</b> : not applicable; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for high risk of bias due to incomplete outcome data and selective reporting.<br/> <sup>b</sup> Downgraded once due to potential risk of bias: unclear details related to methodological design.<br/> <sup>c</sup> Downgraded due to uncertainty: small sample size and wide IQR. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012517-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HC (15 mg/m²/day) versus PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) for treating CAH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HC (15 mg/m²/day) versus PD (3.0 mg/m²/day) versus DXA (0.3 mg/m²/day) for treating CAH</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CAH </p> <p><b>Settings</b>: outpatients, tertiary centre </p> <p><b>Intervention</b>: HC (15 mg/m²/day) or PD (3.0 mg/m²/day) or DXA (0.3 mg/m²/day) </p> <p><b>Comparison</b>: DXA (0.3 mg/m²/day) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>DXA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HC or PD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androgen normalisation</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c,d</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>There were lower levels of 17 OHP reported in the DXA group compared to HC (P &lt; 0.001) and compared to PD (P &lt; 0.001). </p> <p><b>Androstenedione (nmol/L)</b> </p> <p>Androstenedione levels were significantly lower with DXA when compared to HC (P = 0.016) and PD (P = 0.002). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevention of adrenal crisis</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of osteopenia</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of testicular or ovarian adrenal rest tumours</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subfertility</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final adult height</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>17 OHP</b> : 17‐hydroxyprogesterone; <b>CAH</b> : congenital adrenal hyperplasia; <b>CI</b> : confidence interval; <b>DXA</b> : dexamethasone; <b>HC</b> : hydrocortisone; <b>NA</b> : not applicable; <b>PD</b> : prednisolone; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for high risk of bias due to incomplete outcome data and selective reporting.<br/> <sup>b</sup> Downgraded once due to risk of bias: unclear details related to methodological design.<br/> <sup>c</sup> Downgraded due to uncertainty: small sample size so P values should be interpreted with caution.<br/> <sup>d</sup> Downgraded once for lack of applicability as included study only includes children so results are not applicable to adults. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012517-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day) for treating CAH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day) for treating CAH</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CAH </p> <p><b>Settings</b>: outpatients, tertiary centre </p> <p><b>Intervention</b>: HC (10 mg/m²/day to 15 mg/m²/day) </p> <p><b>Comparison</b>: PD (2.4 mg/m²/day to 3.5 mg/m²/day) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>PD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Androgen normalisation</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>The mean level of 17 OHP across the prepubertals and pubertals group in the control group was 1737.00 nmol/L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>The mean level of 17 OHP was <b>1189.10 nmol/L higher</b> (51.08 lower to 2429.28 higher) with HC. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>Data reported separately for pubertal and pre‐pubertal participants. Neither individual result was significant; for the pre‐pubertal participants, MD 1436.00 nmol/L (95% CI ‐127.38 to 2999.38) and for pubertal participants, MD 770.00 nmol/L (95% CI ‐1266.86 to 2806.86). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Androstenedione (nmol/L)</b> </p> <p>The mean level of androstenedione across the prepubertals and pubertals group in the control group was 126.00 nmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Androstenedione (nmol/L)</b> </p> <p>The mean level of androstenedione in the HC group was <b>57.75 nmol/L higher</b> (11.19 higher to 104.31 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androstenedione (nmol/L)</b> </p> <p>Data reported separately for pubertal and pre‐pubertal participants. Neither individual result was significant; for the pre‐pubertal participants, MD 63.00 nmol/L (95% CI ‐4.57 to 130.57) and for pubertal participants, MD 53.00 nmol/L (95% CI ‐11.25 to 117.25). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Testosterone (nmol/L)</b> </p> <p>The mean testosterone level across the prepubertals and pubertals group in the control group was 82.00 nmol/L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Testosterone (nmol/L)</b> </p> <p>The mean testosterone level in the hydrocortisone group was <b>38.55 nmol/L higher</b> (6.48 lower to 83.58 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Testosterone (nmol/L)</b> </p> <p>Data reported separately for pubertal and pre‐pubertal participants. Neither individual result was significant; for the pre‐pubertal participants, MD 35.00 nmol/L (95% CI ‐29.13 to 99.13) and for pubertal participants, MD 42.00 nmol/L (95% CI ‐21.24 to 105.24). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevention of adrenal crisis</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of osteopenia</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of testicular or ovarian adrenal rest tumours</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subfertility</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final adult height</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height velocity in the PD group was 1.12.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height velocity in the HC group was<br/> <b>0.26 higher</b> (0.82 lower to 1.34 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for height velocity which is a surrogate measure for final adult height.</p> <p>The ratio of bone age to chronological age (a further surrogate marker for final adult height) was also measured and results suggest no difference between the groups, MD 0.15 (95% CI ‐0.03 to 0.33). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>17 OHP</b> : 17‐hydroxyprogesterone; <b>CAH</b> : congenital adrenal hyperplasia; <b>CI</b> : confidence interval; <b>DXA</b> : dexamethasone; <b>HC</b> : hydrocortisone; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>PD</b> : prednisolone; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for high risk of bias due to incomplete outcome data and selective reporting.<br/> <sup>b</sup> Downgraded once due to risk of bias: unclear details related to methodological design.<br/> <sup>c</sup> Downgraded once due to imprecision: outcome was downgraded due to imprecision and uncertainty, very large CIs around the MD. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012517-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) for treating CAH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HC (15 mg/m²/day) vsus HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) for treating CAH</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CAH </p> <p><b>Settings</b>: outpatients, tertiary centre </p> <p><b>Intervention</b>: HC (15 mg/m²/day) </p> <p><b>Comparison</b>: HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HC with fludrocortisone </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androgen normalisation</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>Results presented as medians (IQR) and split for prepubertal and pubertal participants. For prepubertals, the levels of 17 OHP were higher in the HC 15 mg/m²/day group, 113.7 (0.5 to 1207) compared to 11.5 (0.6 to 819.9) in the HC 25 mg/m²/day group. For the pubertal group, the levels of 17 OHP were lower in the 15 mg/m²/day group, 91.7 (6.8 to 453.0) compared to 314.2 (66.5 to 568.7) in the HC 25 mg/m²/day group. </p> <p><b>Androstenedione (nmol/L)</b> </p> <p>Results show that for prepubertals androstenedione levels were higher in the HC 15 mg/m²/day group, 3.4 (0.5 to 40.2) compared to the HC 25 mg/m²/day group, 1.6 (0.1 to 31.8). For the pubertal group, androstenedione levels were lower in the HC 15 mg/m²/day group, 11 (6.1 to 41.9) compared to the HC 25 mg/m²/day group, 22.3 (10.5 to 47.5). </p> <p><b>Testosterone (nmol/L)</b> </p> <p>Results show that testosterone levels for prepubertals were higher in the HC 15 mg/m²/day group, 2.5 (0.8 to 9.1) compared to the HC 25 mg/m²/day group, 2.3 (1.2 to 11.3). For the pubertal group, the levels of testosterone were lower in the HC 15 mg/m²/day group, 4.7 (3.9 to 6.9) compared to the HC 25 mg/m²/day group, 6.2 (3.5 to 9.2). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevention of adrenal crisis</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of osteopenia</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of testicular or ovarian adrenal rest tumours</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subfertility</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final adult height</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in height velocity between the 2 groups was<br/> <b>0.34 higher</b> (0.27 higher to 0.41 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for height velocity which is a surrogate measure for final adult height.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>17 OHP</b> : 17‐hydroxyprogesterone; <b>CAH</b> : congenital adrenal hyperplasia; <b>CI</b> : confidence interval; <b>HC</b> : hydrocortisone; <b>IQR</b> : interquartile range; <b>NA</b> : not applicable; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for high risk of bias due to incomplete outcome data and selective reporting.<br/> <sup>b</sup> Downgraded once due to potential risk of bias: unclear details related to methodological design.<br/> <sup>c</sup> Downgraded due to uncertainty: small sample size and wide IQR. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012517-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012517-sec-0037"></div> <section id="CD012517-sec-0038"> <h3 class="title" id="CD012517-sec-0038">Description of the condition</h3> <p>Congenital adrenal hyperplasia (CAH) represents a group of autosomal recessive conditions which lead to glucocorticoid deficiency. It is the most common cause of adrenal insufficiency in children, affecting 1 in 18,000 births in the UK (<a href="./references#CD012517-bbs2-0045" title="KhalidJV , OertonJM , DezateuxC , HindmarshPC , KelnarCJ , KnowlesRL . Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Archives of Disease in Childhood2012;97(2):101–6. ">Khalid 2012</a>), while in other populations, the incidence of CAH ranges from 1 in 5000 to 1 in 20,000 (<a href="./references#CD012517-bbs2-0049" title="MarumudiE , KhadgawatR , SuranaV , ShabirI , JosephA , AmminiAC . Diagnosis and management of classical congenital adrenal hyperplasia. Steroids2013;78(8):741‐6. ">Marumudi 2013</a>; <a href="./references#CD012517-bbs2-0051" title="RiepeFG , SippellWG . Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21‐hydroxylase deficiency. Reviews in Endocrine and Metabolic Disorders2007;8(4):349–63. ">Riepe 2007</a>). In more than 90% of cases, 21‐hydroxylase enzyme deficiency is found; this is caused by mutations in the 21‐hydroxylase gene (CYP21) (<a href="./references#CD012517-bbs2-0049" title="MarumudiE , KhadgawatR , SuranaV , ShabirI , JosephA , AmminiAC . Diagnosis and management of classical congenital adrenal hyperplasia. Steroids2013;78(8):741‐6. ">Marumudi 2013</a>). In most forms of CAH, an enzyme defect blocks cortisol synthesis, thus impairing cortisol‐mediated negative feedback control of adrenocorticotrophic hormone (ACTH) secretion. Oversecretion of ACTH ensues, which results in overstimulation of the adrenals and causes them to enlarge (hyperplasia). This oversecretion also stimulates excessive synthesis of the adrenal products of those pathways unimpaired by an enzyme deficiency. Control of androgens is often highly variable and metabolic abnormalities such as obesity, hypercholesterolaemia, hypertension, insulin resistance and osteopenia have been reported (<a href="./references#CD012517-bbs2-0049" title="MarumudiE , KhadgawatR , SuranaV , ShabirI , JosephA , AmminiAC . Diagnosis and management of classical congenital adrenal hyperplasia. Steroids2013;78(8):741‐6. ">Marumudi 2013</a>). The clinical forms of 21‐hydroxylase enzyme deficiency are typically categorised as classical 21‐hydroxylase deficiency CAH, which is the severe form, or non‐classic (NCAH), which is the mild or late‐onset form. Classical 21‐hydroxylase deficiency also has further subcategories of salt‐wasting (SW) or simple‐virilizing (SV) (also known as non‐salt wasting) forms, depending on the presence of aldosterone deficiency (<a href="./references#CD012517-bbs2-0045" title="KhalidJV , OertonJM , DezateuxC , HindmarshPC , KelnarCJ , KnowlesRL . Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Archives of Disease in Childhood2012;97(2):101–6. ">Khalid 2012</a>). Clinical manifestations in classical 21‐hydroxylase deficiency CAH are due to glucocorticoid deficiency, mineralocorticoid deficiency and androgen excess. The NCAH form is often under‐diagnosed and may be associated with hyperandrogenic symptoms presenting either in childhood (precocious puberty) or later in adulthood (acne, infertility) (<a href="./references#CD012517-bbs2-0049" title="MarumudiE , KhadgawatR , SuranaV , ShabirI , JosephA , AmminiAC . Diagnosis and management of classical congenital adrenal hyperplasia. Steroids2013;78(8):741‐6. ">Marumudi 2013</a>). Biochemical diagnosis of CAH relies on the determination of 17 hydroxyprogesterone (17 OHP); the ACTH stimulation test is the diagnostic test for evaluating adrenal gland function and is used for the biochemical diagnosis of NCAH due to other enzyme deficiencies. A diagnosis of CAH is often further confirmed on genetic testing and urine steroid profiling. </p> </section> <section id="CD012517-sec-0039"> <h3 class="title" id="CD012517-sec-0039">Description of the intervention</h3> <p>The management of individuals with classical 21‐hydroxylase deficiency CAH involves the replacement of glucocorticoids (with oral glucocorticoids, including prednisolone and hydrocortisone), the suppression of ACTH and the replacement of mineralocorticoids to prevent salt wasting. Hydrocortisone is the preferred choice of glucocorticoid replacement in children with CAH, as prednisolone and dexamethasone are associated with growth suppression (Bonfig 2007; <a href="./references#CD012517-bbs2-0048" title="Joint LWPES/ESPE CAH Working Group. Consensus statement on 21‐hydroxylase deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Pediatric Endocrinology. Journal of Clinical Endocrinology and Metabolism2002;87(9):4048‐53. ">LWPES/ESPE 2002</a>). The typical dosing of hydrocortisone in children is 10 to 15 mg/m² per day given in three divided doses. Hydrocortisone is rapidly absorbed from the intestine after oral intake. The bioavailability of hydrocortisone is greater than 90%, but it has a short time to maximum concentration (Tmax) of one to two hours and a short half life of 1.8 to two hours (<a href="./references#CD012517-bbs2-0008" title="CharmandariE , MatthewsD , JohnstonA , BrookCG , HindmarshPC . Serum cortisol and 17‐hydroxyprogesterone interrelation in classic 21‐hydroxylase deficiency: is current replacement therapy satisfactory?. Journal of Clinical Endocrinology and Metabolism2001;86(10):4679‐85. ">Charmandari 2001</a>). Hydrocortisone is highly protein‐bound and there is a high clearance rate with increasing dosage (<a href="./references#CD012517-bbs2-0040" title="FuquaJS , RotensteinD , LeePA . Duration of suppression of adrenal steroids after glucocorticoid administration. International Journal of Pediatric Endocrinology2010;2010:712549. [DOI: 10.1155/2010/712549] ">Fuqua 2010</a>). However, conventional hydrocortisone treatment is associated with reduced quality of life (QoL) and increased side effects on bone metabolism and cardiovascular risks (<a href="./references#CD012517-bbs2-0038" title="DebonoM , PriceJN , RossRJ . Novel strategies for hydrocortisone replacement. Best Practice &amp; Research. Clinical Endocrinology &amp; Metabolism2009;23(2):221–32. ">Debono 2009</a>). </p> <p>Several other regimens have been proposed to mimic the normal physiological endogenous cortisol levels, such as variable intravenous infusions of hydrocortisone (<a href="./references#CD012517-bbs2-0018" title="MerzaZ , Rostami‐HodjeganA , MemmottA , DoaneA , IbbotsonV , Newell‐PriceJ , et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clinical Endocrinology2006;65(1):45–50. ">Merza 2006</a>), multiple dosing of immediate‐release formulation of hydrocortisone tablets or suspension given four‐ to five‐times daily (<a href="./references#CD012517-bbs2-0043" title="HindmarshPC . Management of the child with congenital adrenal hyperplasia. Best Practice &amp; Research. Clinical Endocrinology &amp; Metabolism2009;23(2):193–208. ">Hindmarsh 2009</a>; <a href="./references#CD012517-bbs2-0044" title="HindmarshPC . Mimicking the circadian rhythm in glucocorticoid replacement. BMJ2014;349:g5518. [DOI: 10.1136/bmj.g5518] ">Hindmarsh 2014</a>), dual release (immediate‐release tablet with sustained‐release core) hydrocortisone tablets (<a href="./references#CD012517-bbs2-0011" title="JohannssonG , BergthorsdottirR , NilssonAG , LennernasH , HednerT , SkrticS . Improving glucocorticoid replacement therapy using a novel modified‐release hydrocortisone tablet: A pharmacokinetic study. European Journal of Endocrinology2009;161(1):119‐30. ">Johannsson 2009</a>), modified‐release formulation tablets or suspension of hydrocortisone taken once (<a href="./references#CD012517-bbs2-0026" title="VermaS , VanryzinC , SinaiiN , KimMS , NiemanLK , RavindranS , et al. A pharmacokinetic and pharmacodynamic study of delayed‐ and extended‐release hydrocortisone (Chronocort TM) versus conventional hydrocortisone (Cortef TM) in the treatment of congenital adrenal hyperplasia. Clinical Endocrinology2010;72(4):441‐7. ">Verma 2010</a>) or twice daily (<a href="./references#CD012517-bbs2-0015" title="MallappaA , SinaiiN , KumarP , WhitakerMJ , DaleyL , DigweedD , et al. A Phase 2 study of chronocort, a modified‐release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism2015;100(3):1137–45. ">Mallappa 2015</a>) and a combination of hydrocortisone and prednisolone regimen (<a href="./references#CD012517-bbs2-0006" title="AjishTP , PraveenVP , NishaB , KumarH . Comparison of different glucocorticoid regimens in the management of classical congenital adrenal hyperplasia due to 21‐hydroxylase deficiency.. Indian Journal of Endocrinology and Metabolism2014;18(6):815‐20. ">Ajish 2014</a>). </p> <p>During childhood, the main aims of medical treatment of 21‐hydroxylase deficiency CAH are to prevent adrenal crisis and to achieve normal stature, optimal adult height and to undergo normal puberty. In adulthood, the aims of medical treatment are to prevent adrenal crisis, ensure normal fertility and to avoid the long‐term consequences of glucocorticoid use. </p> </section> <section id="CD012517-sec-0040"> <h3 class="title" id="CD012517-sec-0040">How the intervention might work</h3> <p>Current treatment regimens for CAH with glucocorticoids cannot optimally replicate the normal physiological cortisol level (<a href="./references#CD012517-bbs2-0018" title="MerzaZ , Rostami‐HodjeganA , MemmottA , DoaneA , IbbotsonV , Newell‐PriceJ , et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clinical Endocrinology2006;65(1):45–50. ">Merza 2006</a>). Over‐treatment or under‐treatment of CAH is often reported in individuals who may be treated with different steroid treatment regimens. Conventional twice‐ or three‐times‐daily hydrocortisone replacement therapy does not replicate the normal circadian rhythm, as cortisol levels are always low in the early hours of the morning when endogenous cortisol levels are normally rising. This then drives a nocturnal rise in ACTH which increases the production of androgens (<a href="./references#CD012517-bbs2-0008" title="CharmandariE , MatthewsD , JohnstonA , BrookCG , HindmarshPC . Serum cortisol and 17‐hydroxyprogesterone interrelation in classic 21‐hydroxylase deficiency: is current replacement therapy satisfactory?. Journal of Clinical Endocrinology and Metabolism2001;86(10):4679‐85. ">Charmandari 2001</a>). Under‐treatment and the resulting excess production of androgens causes virilization, accelerated growth, advanced skeletal maturation and early epiphyseal fusion (<a href="./references#CD012517-bbs2-0051" title="RiepeFG , SippellWG . Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21‐hydroxylase deficiency. Reviews in Endocrine and Metabolic Disorders2007;8(4):349–63. ">Riepe 2007</a>). Conversely, a longer‐acting cortisol regimen bears the risk of over‐treatment and if taken at night will expose individuals to high levels of steroid at the time of the cortisol nadir. Over‐treatment often leads to side effects such as obesity, hypertension and osteoporosis (<a href="./references#CD012517-bbs2-0055" title="SubbarayanA , DattaniMT , PetersCJ , HindmarshPC . Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21‐hydroxylase deficiency. Clinical Endocrinology2014;80(4):471–7. ">Subbarayan 2014</a>). In some regimens, reverse circadian rhythm pattern of hydrocortisone replacement has been used, where a higher dose is given at night in order to suppress overnight increases in ACTH rather than giving the highest dose of hydrocortisone in the morning. </p> </section> <section id="CD012517-sec-0041"> <h3 class="title" id="CD012517-sec-0041">Why it is important to do this review</h3> <p>There is no current standard treatment for 21‐hydroxylase deficiency CAH and physicians often customise treatment for each individual using various regimens. It remains unclear which treatment regimen is most effective (<a href="./references#CD012517-bbs2-0050" title="RiepeFG , KroneN , ViemannM , PartschCJ , SippellWG . Management of congenital adrenal hyperplasia: results of the ESPE questionnaire. Hormone Research2002;58(4):196‐205. ">Riepe 2002</a>). The pharmacokinetics and pharmacodynamics of currently available glucocorticoid regimens do not allow the matching of the hormonal fluctuations and the physiological requirements in people with 21‐hydroxylase deficiency CAH and there is much debate as to which is the most efficacious regimen used for the treatment of CAH (<a href="./references#CD012517-bbs2-0018" title="MerzaZ , Rostami‐HodjeganA , MemmottA , DoaneA , IbbotsonV , Newell‐PriceJ , et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clinical Endocrinology2006;65(1):45–50. ">Merza 2006</a>). This review aims to establish evidence of efficacy for the different treatment regimens of cortisol replacement in people with 21‐hydroxylase deficiency CAH and will separately examine trials comparing the different glucocorticoid replacement regimens in the treatment of 21‐hydroxylase deficiency CAH. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012517-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012517-sec-0042"></div> <p>To compare and determine the efficacy and safety of different glucocorticoid replacement regimens in the treatment of 21‐hydroxylase deficiency CAH in children and adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012517-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012517-sec-0043"></div> <section id="CD012517-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012517-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included any randomised controlled trials (RCTs) or quasi‐RCTs (where method of allocation is not truly random), of both parallel and cross‐over design (but not cluster RCTs), comparing different glucocorticoid replacement regimens in the treatment of 21‐hydroxylase deficiency CAH in children and adults. </p> </section> <section id="CD012517-sec-0046"> <h4 class="title">Types of participants</h4> <p>Children and adults diagnosed with 21‐hydroxylase deficiency CAH according to the appropriate diagnostic criteria of the time. A child is defined as under 18 years of age. </p> </section> <section id="CD012517-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Any circadian, extended release or conventional hydrocortisone replacement regimen (no dose restrictions) of any duration for treating congenital adrenal hyperplasia in children and adults. We compared the following active interventions to each other if they were reported: </p> <p> <ul id="CD012517-list-0001"> <li> <p>daily Plenadren<sup>®</sup> (an immediate‐release tablet with sustained‐release hydrocortisone core formulation); </p> </li> <li> <p>daily Chronocort<sup>®</sup> (a modified‐release formulation of hydrocortisone); </p> </li> <li> <p>twice‐daily Chronocort<sup>®</sup> (a modified‐release formulation of hydrocortisone); </p> </li> <li> <p>three‐times daily conventional immediate‐release formulation of hydrocortisone;</p> </li> <li> <p>more than three‐times daily conventional immediate‐release formulation of hydrocortisone;</p> </li> <li> <p>24‐hour circadian continuous subcutaneous infusion of hydrocortisone;</p> </li> <li> <p>combination of oral hydrocortisone and prednisolone regimen.</p> </li> </ul> </p> <p>The mineralocorticoid replacement dosing will not be compared.</p> </section> <section id="CD012517-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD012517-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012517-list-0002"> <li> <p>QoL score (as assessed by Short Form Health Survey (SF‐36))</p> </li> <li> <p>Androgen normalisation (defined by 17 OHP monitoring)</p> </li> <li> <p>Prevention of adrenal crisis</p> </li> </ol> </p> </section> <section id="CD012517-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012517-list-0003"> <li> <p>Presence of osteopenia (bone mineral density (BMD) measured by dual X‐ray absorptiometry (DEXA)) </p> </li> <li> <p>Presence of testicular or ovarian adrenal rest tumours</p> </li> <li> <p>Subfertility (defined by history, evidence of adrenal progesterone hypersecretion, consequences of genital reconstructive surgery, secondary polycystic ovaries syndrome) </p> </li> <li> <p>Final adult height in standard deviation score (SDS)</p> </li> </ol> </p> </section> </section> </section> <section id="CD012517-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>The authors searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD012517-sec-0052"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Cystic Fibrosis and Genetic Disorders Group's Information Specialist conducted a search of the Group's Inborn Errors of Metabolism Trials Register using the keyword: congenital adrenal hyperplasia. </p> <p>The Inborn Errors of Metabolism Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated with each new issue of the Cochrane Library), weekly searches of MEDLINE and the prospective handsearching of one journal ‐ <i>Journal of Inherited Metabolic Disease</i>. Unpublished work is identified by searching through the abstract books of the Society for the Study of Inborn Errors of Metabolism conference and the SHS Inborn Error Review Series. For full details of all searching activities for the register, please see the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the most recent search of the Group's Inborn Errors of Metabolism Trials Register: 24 June 2019. </p> <p>The authors searched the following databases, registers and trial registries:</p> <p> <ul id="CD012517-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 12) in the Cochrane Library (searched 17 December 2019); </p> </li> <li> <p>MEDLINE Ovid (1946 to 17 December 2019);</p> </li> <li> <p>HDAS Embase (1974 to 17 December 2019);</p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>; searched 17 December 2019); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 17 December 2019); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 17 December 2019); </p> </li> <li> <p>Health Canada’s Clinical Trial Database (<a href="https://health-products.canada.ca/ctdb-bdec/index-eng.jsp" target="_blank">health‐products.canada.ca/ctdb‐bdec/index‐eng.jsp</a>; searched 17 December 2019); </p> </li> <li> <p>NICE Evidence (<a href="http://www.evidence.nhs.uk" target="_blank">www.evidence.nhs.uk</a>; searched 17 December 2019). </p> </li> </ul> </p> <p>For details of the search strategies, please see <a href="./appendices#CD012517-sec-0120">Appendix 1</a>. </p> </section> <section id="CD012517-sec-0053"> <h4 class="title">Searching other resources</h4> <p>The authors checked the bibliographies of included studies and also any relevant systematic reviews and health technology assessment (HTA) reports identified for further references to relevant trials. They also hand searched <a href="http://www.endocrine-abstracts.org" target="_blank">www.endocrine‐abstracts.org</a> from 2001 to 2019. </p> </section> </section> <section id="CD012517-sec-0054"> <h3 class="title" id="CD012517-sec-0054">Data collection and analysis</h3> <p>One author (KS) conducted an initial search and undertook an initial sift of the search results to identify potentially relevant articles. Both authors (KS and SN) then independently assessed the articles for eligibility. </p> <section id="CD012517-sec-0055"> <h4 class="title">Selection of studies</h4> <p>To determine the trials for further assessment, two review authors (SN, KS) independently scanned the abstract and title of every record retrieved. They reviewed the full texts of all potentially relevant articles.If there were any differences in opinion, the review authors planned to resolve these by consensus and with an independent advisor. If it was not possible to resolve a disagreement regarding trial selection, the review authors planned to add the article to those 'Awaiting assessment' and planned to contact the trial investigators for clarification. There was no disagreement on trial selection, therefore an independent advisor was not required. </p> <section id="CD012517-sec-0056"> <h5 class="title">Dealing with duplicate publications</h5> <p>In the case of duplicate publications and companion papers of a primary paper, the review authors extracted all available information from all publications. In cases of doubt, the review authors obtained the original publication (usually the oldest version) as a priority. We have listed all publications relating to each unique trial under a single trial ID. </p> </section> </section> <section id="CD012517-sec-0057"> <h4 class="title">Data extraction and management</h4> <p>The authors extracted data using the Cochrane Cystic Fibrosis and Genetic Disorders Review Group's trial selection, quality assessment and data extraction form, adapted to suit the outcomes of this review. They recorded trial design, trial participant characteristics, and outcome data and would have resolved any disagreements by discussion, or if required by a third party, if they had occurred. They also measured the inter‐rater agreement for trial selection using the kappa statistic (<a href="./references#CD012517-bbs2-0037" title="CohenJ . A coefficient of agreement for nominal scales. Educational and Psychological Measurement1960;20(1):37–46. ">Cohen 1960</a>). The review authors would have requested any relevant missing information from the trial investigators, if this had been required. The reviewers had planned to analyse the data from different interventions separately, but due to the data limitations were only able to report results narratively. </p> <p>The review authors reported outcome data at the following intervals:</p> <p> <ul id="CD012517-list-0005"> <li> <p>short term: less than 12 months;</p> </li> <li> <p>medium term: one to five years;</p> </li> <li> <p>long term: more than five years.</p> </li> </ul> </p> <p>If trials reported multiple time points within the time frames described above (e.g. three months and six months) then the review authors presented any additional individual time points, but still described the results as 'short term', 'medium term' or 'long term' as appropriate. </p> </section> <section id="CD012517-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The authors used the Cochrane risk of bias tool to assess the following criteria: randomisation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; and selective reporting (<a href="./references#CD012517-bbs2-0042" title="HigginsJP , AltmanDG , Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). They classified the risks as low, high or unclear and recorded each decision and their reasons for the judgement in a table; they also displayed the assessments in the overall risk of bias summary. </p> </section> <section id="CD012517-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>The authors planned to follow recommendations for data analysis set out in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012517-bbs2-0039" title="DeeksJJ , HigginsJP , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). They have presented data in the graphs; however, they were not able to combine data to perform any meta‐analysis due to considerable heterogeneity in the trials. </p> <p>For dichotomous outcomes, (such as presence of osteoporosis, testicular or ovarian tumours, hypertension, hypercholesterolaemia or obesity) the authors planned to analyse the treatment effect using risk ratios (RR), however, they were not able to undertake this due to the limited data<i>.</i> Considering the outcome measures listed, as the authors expected, most of the data collected for this review was continuous. They extracted means and standard deviations (SDs) from the trials where possible. </p> </section> <section id="CD012517-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>The authors implemented the following strategies to minimize the impact of non‐standard designs upon the conclusions of the review. Despite initially planning on considering cluster RCTs for this review and discussing this in the protocol, on reflection they decided that the trial design was not appropriate and amended the review's inclusion criteria. </p> <p>The authors included cross‐over trials and analysed data from one of these in the review (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). Although they planned to analyse only first‐arm data for cross‐over trials, the data available only allowed them to analyse the height data from the Silva trial using GIV analysis (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). They entered the MD between treatment arms at six months into the GIV calculations and then derived the standard error (SE) from the published P value. The authors have reported results from the remaining three cross‐over trials narratively (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> </section> <section id="CD012517-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>If data were missing from the included trials, the review authors made every effort to contact the original trial authors to obtain these data. If data such as standard deviations (SDs) were missing, where appropriate, the authors planned to calculate these from SEs, CIs, T‐values or P values (if reported). In the event of large scale missing data or participant attrition, authors planned to carry out an intention‐to‐treat analysis but no trials reported participant attrition rates. Bias can result from the imperfect nature of estimates by imputation; to protect against this the authors carried out an available‐case analysis dealing with participants who completed the trial. If this occurred, the authors had planned to conduct sensitivity analysis but due to limited data this was not possible. </p> </section> <section id="CD012517-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>Authors planned to assess heterogeneity using the I² statistic, which gives insight into the level of variability within results that is due to heterogeneity as opposed to chance alone (<a href="./references#CD012517-bbs2-0041" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The authors planned to assess heterogeneity in terms of overlapping percentage intervals: 0% to 40% (might not be important); 30% to 60% (may represent moderate heterogeneity); 50% to 90% (may represent substantial heterogeneity); and 75% to 100% (may represent considerable heterogeneity) (<a href="./references#CD012517-bbs2-0039" title="DeeksJJ , HigginsJP , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). However, due to limited data, this was not possible. </p> </section> <section id="CD012517-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>A comprehensive search strategy, including grey literature, protected against many forms of publication bias. The authors note, however, that this method alone would not prevent all possibility of publication bias infiltrating the review. Therefore, if the authors had identified and incorporated more than 10 trials, they would have further assessed publication bias using funnel plots. The authors planned to visually assess the funnel plots they generated to assess asymmetry and consider the descriptive characteristics of the plot. Further to visual inspection, authors also planned to assess funnel plot asymmetry using an adaptation of the linear regression model (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011665/full#CD011665-bbs2-0014" target="_blank">Eggar 1997</a>). </p> <p>In order to examine possible selective reporting bias, the review authors requested trial protocols from two original trial authors but have received no response to date (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> </section> <section id="CD012517-sec-0064"> <h4 class="title">Data synthesis</h4> <p>The authors have used fixed‐effect analyses in this review as a pooled effect estimate from a fixed‐effect meta‐analysis is normally interpreted as being the best estimate of the intervention effect. For future updates, where heterogeneity cannot be explained by the pre‐specified subgroup analyses, the authors plan to perform a sensitivity analysis using a random‐effects model. If a future meta‐analysis is not appropriate (e.g. a substantial level of heterogeneity), the review authors will present a narrative within the results section. </p> </section> <section id="CD012517-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If sufficient data had been available and at least moderate heterogeneity had been present (as defined above), the authors planned to conduct subgroup analyses based on children (younger than 18 years of age) and adults (18 years and older) for the outcome final adult height within the different intervention categories. The achievement of final adult height for children with this condition is an important aspect of optimal management and the rationale for this subgroup analysis was a possible impact of steroid use in children on their delayed growth, puberty and their final height. </p> <p>Lai previously showed that mean height after age of 18 years is significantly lower in boys previously treated with prednisolone (PD) versus placebo (<a href="./references#CD012517-bbs2-0046" title="LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , FarrellPM . Risk of persistent growth impairment after alternate‐day prednisone treatment in children with cystic fibrosis.. N Engl J Med. 23 March 2000;342(12):851‐9. ">Lai 2000</a>). In adults, there are significant reductions in bone mineral density (BMD) associated with the use of PD (or equivalent) and fracture risk increased within three to six months of treatment initiation; this increased fracture risk was independent of the individual's age, gender and the underlying disease (<a href="./references#CD012517-bbs2-0056" title="vanStaaTP , LeufkensHG , CooperC . The epidemiology of corticosteroid‐induced osteoporosis: a meta‐analysis.. Osteoporos Int.Oct 2002;13(10):777‐87. ">van Staa 2002</a>). However, due to limited data, the proposed subgroup analysis was not possible. </p> <p>The authors do not propose any subgroup analyses by age for any other outcomes.</p> </section> <section id="CD012517-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>If authors had found data were incomplete, if they had needed to impute data, or if criteria limits were poorly defined (such as age ranges, or what constitutes 'standard care') they planned to undertake sensitivity analyses. If appropriate, they would have completed the meta‐analyses with and without the contentious data to assess its impact upon the overall findings. If the results of the meta‐analyses were not greatly altered, the robustness of the review would be increased. If results of the two analyses had differed greatly, then they would have interpreted the results of the review with caution.The authors planned to avoid this by conducting a sensitivity analysis at the participant level and incorporating adjustment using the intra‐class correlation coefficient (ICC). </p> <p>If the authors had identified different levels of potential bias in trials, they would have conducted sensitivity analyses. If they judged some trials to contain potentially high or uncertain levels of bias, they would have omitted these from the analyses. This again would allow the reviewers to identify the impact of these trials upon the results of the analyses. If there had been no marked difference in results due to this omission, it would have strengthened the conclusions of the review by indicating that they were not in fact impacted by the potential bias of the trials. </p> <p>If any heterogeneity could not be explained by the pre‐specified subgroup analyses, the authors would have performed a sensitivity analysis using a random‐effects model. </p> <section id="CD012517-sec-0067"> <h5 class="title">Summary of findings table</h5> <p>The authors presented a 'Summary of findings' table for each comparison to present the main findings of a review in a transparent and simple tabular format (<a href="./full#CD012517-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012517-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012517-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012517-tbl-0004">summary of findings Table 4</a>). In particular, to provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the primary and secondary outcomes listed below. </p> <p> <ol id="CD012517-list-0006"> <li> <p>QoL score</p> </li> <li> <p>Androgen normalisation</p> </li> <li> <p>Prevention of adrenal crisis</p> </li> <li> <p>Presence of osteopenia</p> </li> <li> <p>Presence of testicular adrenal rest tumours (in boys)</p> </li> <li> <p>Subfertility</p> </li> <li> <p>Final adult height in SDS</p> </li> </ol> </p> <p>The authors used GRADE to evaluate the quality of the evidence (<a href="./references#CD012517-bbs2-0052" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>; <a href="./references#CD012517-bbs2-0053" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011b</a>).The GRADE approach uses five considerations (trial limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for specific outcomes. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, inconsistency, imprecision of effect estimates or publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012517-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012517-sec-0068"></div> <section id="CD012517-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD012517-sec-0070"> <h4 class="title">Results of the search</h4> <p>The searches identified 1729 records; after initial screening 31 publications and 12 trial registry entries were selected for further examination. After screening the full texts of the selected papers and the registry entries, only five trials (six references), all of which were published as full papers, met the inclusion criteria; 23 studies (26 references) were excluded, two studies (one reference each) listed as 'Awaiting classification' and six trials (nine registry entries) were listed as ongoing (<a href="#CD012517-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012517-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012517-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012517-sec-0071"> <h4 class="title">Included studies</h4> <p>Five trials (n = 101) were included in the review (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). There was a large variation between the trials identified in terms of design, intervention, duration of treatment and outcome measures. See <a href="./references#CD012517-sec-0130" title="">Characteristics of included studies</a> table for full details. </p> <section id="CD012517-sec-0072"> <h5 class="title">Trial design</h5> <p>Four trials were of cross‐over design (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>) and one was of parallel design (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). Duration of treatment ranged from two weeks (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>) to six months per treatment arm (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>) with an overall follow‐up between six and 12 months for all trials. Four trials were single centre (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>) and one was multicentre (two centres) (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). All trials were undertaken in tertiary endocrine centres. </p> </section> <section id="CD012517-sec-0073"> <h5 class="title">Participants</h5> <p>All trials included both males and females with a confirmed diagnosis of CAH (n = 101). Sample size varied from six participants (<a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>) to 44 participants (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). The age of participants ranged from 1.2 months (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>) to 21 years (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). Three trials were limited to children of both genders with confirmed diagnosis of CAH (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). </p> </section> <section id="CD012517-sec-0074"> <h5 class="title">Interventions</h5> <p>All trials employed an oral glucocorticoid replacement therapy, but with different daily schedules and dose levels (calculated by body surface area (BSA) mg/m²) as described below. Three trials compared different dose schedules of hydrocortisone (HC) (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>), one three‐arm trial compared HC to PD and dexamethasone (DXA) (<a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>) and one trial compared HC with fludrocortisone to PD with fludrocortisone (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). </p> <p>Of the three trials using HC, one trial compared two different regimens of three times daily HC of 13.5 mg/m²/day to 15.5 mg/m²/day where one group was given a morning high dose (50% of the daily HC in the morning followed by 25% at midday and 25% at night) and the second group was given an evening high dose (25% of daily HC in the morning and at midday followed by 50% at bedtime) (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>). A second trial compared HC 15 mg/m²/day to HC 25 mg/m²/day given as once‐daily doses (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). The third trial compared five different regimens of three times daily HC with a total daily dose of 12.5 mg/m² as shown in the table (<a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> <p> <div class="table" id="CD012517-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Morning dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Midday dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Evening dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>full daily HC dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/3 full daily HC dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/3 full daily HC dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/3 full daily HC dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/3 full daily HC dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/3 full daily HC dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/3 full daily HC dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/3 full daily HC dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>full daily HC dose</p> </td> </tr> </tbody> </table> </div> </p> <p>A three‐arm trial compared three times daily HC with a total daily dose of 15 mg/m²/day to twice‐daily PD with a total daily dose of 3 mg/m²/day and to once‐daily DXA at a dose of 0.3 mg/m²/day (<a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>). </p> <p>The remaining trial compared three times daily HC 10 mg/m² and fludrocortisone 0.1 mg/day versus 15 mg/m² to once‐daily PD 2.4 mg/m² to 3.5 mg/m² with fludrocortisone 0.1 mg/day (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). </p> </section> <section id="CD012517-sec-0075"> <h5 class="title">Outcome measures</h5> <p>Five trials reported 17 OHP levels (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). Four trials reported on adrenal androgens, such as testosterone (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>), four trials reported on androstenedione (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>) and one trial reported on dehydroepiandrosterone sulphate (DHEAS) (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>). Three trials reported on growth and bone maturation (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). Two trials also reported on height velocity (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). </p> <p>No trial reported on our outcomes of QoL, prevention of adrenal crisis, presence of osteopenia or testicular or ovarian adrenal rest tumours or subfertility. However three trials reported outcomes not included in our review. One trial reported on sleep patterns and daytime activities (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>); a further trial reported on plasma ACTH, cortisol,11‐deoxycortisol,17‐hydroxysteroids and pregnanetriol (<a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>); and a third trial reported on ACTH (<a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>). </p> </section> </section> <section id="CD012517-sec-0076"> <h4 class="title">Excluded studies</h4> <p>A total of 23 trials were excluded for a variety of reasons as stated in the tables (<a href="./references#CD012517-sec-0131" title="">Characteristics of excluded studies</a>). Nine trials were not RCTs or quasi‐RCTs (<a href="./references#CD012517-bbs2-0006" title="AjishTP , PraveenVP , NishaB , KumarH . Comparison of different glucocorticoid regimens in the management of classical congenital adrenal hyperplasia due to 21‐hydroxylase deficiency.. Indian Journal of Endocrinology and Metabolism2014;18(6):815‐20. ">Ajish 2014</a>; <a href="./references#CD012517-bbs2-0007" title="BonfigW , BechtoldS , SchmidtH , KnorrD , SchwarzHP . Reduced final height outcome in congenital adrenal hyperplasia under prednisone: deceleration of growth velocity during puberty. Journal of Clinical Endocrinology and Metabolism2007;92(5):1635‐9. ">Bonfig 2007</a>; <a href="./references#CD012517-bbs2-0008" title="CharmandariE , MatthewsD , JohnstonA , BrookCG , HindmarshPC . Serum cortisol and 17‐hydroxyprogesterone interrelation in classic 21‐hydroxylase deficiency: is current replacement therapy satisfactory?. Journal of Clinical Endocrinology and Metabolism2001;86(10):4679‐85. ">Charmandari 2001</a>; <a href="./references#CD012517-bbs2-0015" title="MallappaA , SinaiiN , KumarP , WhitakerMJ , DaleyL , DigweedD , et al. A Phase 2 study of chronocort, a modified‐release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism2015;100(3):1137–45. ">Mallappa 2015</a>; <a href="./references#CD012517-bbs2-0018" title="MerzaZ , Rostami‐HodjeganA , MemmottA , DoaneA , IbbotsonV , Newell‐PriceJ , et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clinical Endocrinology2006;65(1):45–50. ">Merza 2006</a>; <a href="./references#CD012517-bbs2-0020" title="NeumannU , WhitakerMJ , WiegandS , KrudeH , PorterJ , DaviesM , et al. Absorption and tolerability of taste‐masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clinical Endocrinology2018;88(1):21‐9. ">Neumann 2018</a>; <a href="./references#CD012517-bbs2-0021" title="PanamontaO , ThinkhamropB , KirdponW , PudtawaroLO , SungsahachartD . Adrenocorticotropin stimulation test in congenital adrenal hyperplasia: comparison between standard and low dose test. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2003;86(7):634‐40. [CENTRAL: 559097; CRS: 5500050000000554; EMBASE: 2003380852; PUBMED: 12948258] ">Panamonta 2003</a>; <a href="./references#CD012517-bbs2-0022" title="EUCTR2015‐003996‐32‐FR . Multicentric evaluation of in utero dexamethasone (DEX) on the cognitive development of children at risk of congenital adrenal hyperplasia ‐ PRENATAL DEX Study. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015‐003996‐32‐FR (first received 04 December 2015). ">PRENATAL DEX</a>; <a href="./references#CD012517-bbs2-0026" title="VermaS , VanryzinC , SinaiiN , KimMS , NiemanLK , RavindranS , et al. A pharmacokinetic and pharmacodynamic study of delayed‐ and extended‐release hydrocortisone (Chronocort TM) versus conventional hydrocortisone (Cortef TM) in the treatment of congenital adrenal hyperplasia. Clinical Endocrinology2010;72(4):441‐7. ">Verma 2010</a>) and the remaining trials did not have HC regimens as the intervention. </p> <section id="CD012517-sec-0077"> <h5 class="title">Studies awaiting classification</h5> <p>The search also identified two trials which are listed as 'Awaiting classification' pending full publication or further information from the investigators (<a href="./references#CD012517-bbs2-0029" title="SaludJLMF , Ramos‐AbadL . A pilot study on the effect of three hydrocortisone dosing regimen on 17 hydroxyprogesterone levels in patients with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2013;Suppl 1:P123. ">Salud 2013</a>; <a href="./references#CD012517-bbs2-0030" title="SilvaIN , Oliveira‐JuniorDF , SimalCJ , VianaMB , ChagasAJ . Morning steroid profile in children with congenital adrenal hyperplasia under different hydrocortisone schedules. Indian Journal of Pediatrics1994;61(4):341‐6. ">Silva 1994</a>). Both seem to be RCTs and have relevant interventions and outcomes. However, one trial has only been published as a conference abstract; we have attempted to contact the authors for more information, but to date we have not received a reply (<a href="./references#CD012517-bbs2-0029" title="SaludJLMF , Ramos‐AbadL . A pilot study on the effect of three hydrocortisone dosing regimen on 17 hydroxyprogesterone levels in patients with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2013;Suppl 1:P123. ">Salud 2013</a>). We have only been able to access the abstract of the second RCT and will further evaluate when we are able to obtain the full article (<a href="./references#CD012517-bbs2-0030" title="SilvaIN , Oliveira‐JuniorDF , SimalCJ , VianaMB , ChagasAJ . Morning steroid profile in children with congenital adrenal hyperplasia under different hydrocortisone schedules. Indian Journal of Pediatrics1994;61(4):341‐6. ">Silva 1994</a>). </p> </section> <section id="CD012517-sec-0078"> <h5 class="title">Ongoing studies</h5> <p>Six ongoing trials were identified from trials registries (<a href="./references#CD012517-bbs2-0031" title="NCT03760835 . Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME). clinicaltrials.gov/show/nct03760835 (first received 30 November 2018). ">CareOnTIME</a>; <a href="./references#CD012517-bbs2-0032" title="NCT02552251 . COrticosteroid in congenital adrenal hyperplasia (COCA). clinicaltrials.gov/show/NCT02552251 (first received 17 September 2015). ">COCA</a>; <a href="./references#CD012517-bbs2-0033" title="EUCTR2011‐005822‐23‐NO . A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐005822‐23‐NO (first received 25 February 2013). NCT01771328 . Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia. clinicaltrials.gov/show/nct01771328 (first received 18 January 2013). ">NCT01771328</a>; <a href="./references#CD012517-bbs2-0034" title="EUCTR2015‐000711‐40‐NL . Chronocort®, a slow release medicinal preparation of hydrocortisone, will be compared with currently used glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia seeking to assess its safety, tolerability and effectiveness. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015‐000711‐40‐NL (first received 17 November 2015). NCT02716818 . Comparison of chronocort® with standard glucocorticoid therapy in patients with congenital adrenal hyperplasia. clinicaltrials.gov/show/NCT02716818 (first received 23 March 2016). ">NCT02716818</a>; <a href="./references#CD012517-bbs2-0035" title="EUCTR2012‐001104‐37‐GB . Pulses study [Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia ‐ the pulses study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐001104‐37‐GB (first received 24 July 2014). ISRCTN67193733 . The Pulses Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN67193733 (first received 03 December 2014). ">PULSES</a>; <a href="./references#CD012517-bbs2-0036" title="NCT03532022 . Open‐label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE). clinicaltrials.gov/show/nct03532022 (first received 22 May 2018). ">RESTORE</a>). </p> <section id="CD012517-sec-0079"> <h6 class="title">Trial design</h6> <p>Two trials are of cross‐over design (<a href="./references#CD012517-bbs2-0032" title="NCT02552251 . COrticosteroid in congenital adrenal hyperplasia (COCA). clinicaltrials.gov/show/NCT02552251 (first received 17 September 2015). ">COCA</a>; <a href="./references#CD012517-bbs2-0033" title="EUCTR2011‐005822‐23‐NO . A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐005822‐23‐NO (first received 25 February 2013). NCT01771328 . Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia. clinicaltrials.gov/show/nct01771328 (first received 18 January 2013). ">NCT01771328</a>) and four are of parallel design (<a href="./references#CD012517-bbs2-0031" title="NCT03760835 . Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME). clinicaltrials.gov/show/nct03760835 (first received 30 November 2018). ">CareOnTIME</a>; <a href="./references#CD012517-bbs2-0034" title="EUCTR2015‐000711‐40‐NL . Chronocort®, a slow release medicinal preparation of hydrocortisone, will be compared with currently used glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia seeking to assess its safety, tolerability and effectiveness. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015‐000711‐40‐NL (first received 17 November 2015). NCT02716818 . Comparison of chronocort® with standard glucocorticoid therapy in patients with congenital adrenal hyperplasia. clinicaltrials.gov/show/NCT02716818 (first received 23 March 2016). ">NCT02716818</a>; <a href="./references#CD012517-bbs2-0035" title="EUCTR2012‐001104‐37‐GB . Pulses study [Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia ‐ the pulses study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐001104‐37‐GB (first received 24 July 2014). ISRCTN67193733 . The Pulses Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN67193733 (first received 03 December 2014). ">PULSES</a>; <a href="./references#CD012517-bbs2-0036" title="NCT03532022 . Open‐label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE). clinicaltrials.gov/show/nct03532022 (first received 22 May 2018). ">RESTORE</a>). Duration of treatment ranged from six weeks (<a href="./references#CD012517-bbs2-0035" title="EUCTR2012‐001104‐37‐GB . Pulses study [Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia ‐ the pulses study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐001104‐37‐GB (first received 24 July 2014). ISRCTN67193733 . The Pulses Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN67193733 (first received 03 December 2014). ">PULSES</a>) to 52 weeks per treatment arm (<a href="./references#CD012517-bbs2-0036" title="NCT03532022 . Open‐label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE). clinicaltrials.gov/show/nct03532022 (first received 22 May 2018). ">RESTORE</a>). All six trials were single centre and undertaken in tertiary endocrine centres. </p> </section> <section id="CD012517-sec-0080"> <h6 class="title">Participants</h6> <p>Five trials included both males and females with a confirmed diagnosis of CAH (n = 546); one trial included only female participants (n = 40) (<a href="./references#CD012517-bbs2-0032" title="NCT02552251 . COrticosteroid in congenital adrenal hyperplasia (COCA). clinicaltrials.gov/show/NCT02552251 (first received 17 September 2015). ">COCA</a>). Sample size varied from 20 participants (<a href="./references#CD012517-bbs2-0033" title="EUCTR2011‐005822‐23‐NO . A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐005822‐23‐NO (first received 25 February 2013). NCT01771328 . Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia. clinicaltrials.gov/show/nct01771328 (first received 18 January 2013). ">NCT01771328</a>) to 150 participants (<a href="./references#CD012517-bbs2-0031" title="NCT03760835 . Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME). clinicaltrials.gov/show/nct03760835 (first received 30 November 2018). ">CareOnTIME</a>). The age of participants was 18 years and above in five trials and 16 years and above in one trial (<a href="./references#CD012517-bbs2-0036" title="NCT03532022 . Open‐label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE). clinicaltrials.gov/show/nct03532022 (first received 22 May 2018). ">RESTORE</a>). </p> </section> <section id="CD012517-sec-0081"> <h6 class="title">Interventions</h6> <p>All trials employed an oral glucocorticoid replacement therapy, but with different daily schedules and dose levels or mode of administration. One trial compared standard glucocorticoids (HC, cortisone, PD, prednisone, DXA) with dual release HC tablet administered in one dose per day (<a href="./references#CD012517-bbs2-0031" title="NCT03760835 . Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME). clinicaltrials.gov/show/nct03760835 (first received 30 November 2018). ">CareOnTIME</a>). One three‐arm trial assessed the impact of physiological doses of HC, DXA or PD on biochemical parameters (<a href="./references#CD012517-bbs2-0032" title="NCT02552251 . COrticosteroid in congenital adrenal hyperplasia (COCA). clinicaltrials.gov/show/NCT02552251 (first received 17 September 2015). ">COCA</a>). A further trial examined a subcutaneous infusion of HC 10 mg/m²/24 hours as compared to cortisone acetate tablets (<a href="./references#CD012517-bbs2-0033" title="EUCTR2011‐005822‐23‐NO . A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐005822‐23‐NO (first received 25 February 2013). NCT01771328 . Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia. clinicaltrials.gov/show/nct01771328 (first received 18 January 2013). ">NCT01771328</a>). A fourth trial compared a HC regimen with PD alone or PD plus HC and with DXA (<a href="./references#CD012517-bbs2-0034" title="EUCTR2015‐000711‐40‐NL . Chronocort®, a slow release medicinal preparation of hydrocortisone, will be compared with currently used glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia seeking to assess its safety, tolerability and effectiveness. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015‐000711‐40‐NL (first received 17 November 2015). NCT02716818 . Comparison of chronocort® with standard glucocorticoid therapy in patients with congenital adrenal hyperplasia. clinicaltrials.gov/show/NCT02716818 (first received 23 March 2016). ">NCT02716818</a>). The PULSES trial compared HC with a placebo infusion to oral placebo and a HC infusion (<a href="./references#CD012517-bbs2-0035" title="EUCTR2012‐001104‐37‐GB . Pulses study [Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia ‐ the pulses study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐001104‐37‐GB (first received 24 July 2014). ISRCTN67193733 . The Pulses Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN67193733 (first received 03 December 2014). ">PULSES</a>). The final trial compared HC modified release doses of 5 mg, 10 mg and 20 mg with HC, DXA, PD or prednisone treatment (<a href="./references#CD012517-bbs2-0036" title="NCT03532022 . Open‐label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE). clinicaltrials.gov/show/nct03532022 (first received 22 May 2018). ">RESTORE</a>). </p> </section> <section id="CD012517-sec-0082"> <h6 class="title">Outcome measures</h6> <p>Five trials plan to report 17 OHP (<a href="./references#CD012517-bbs2-0032" title="NCT02552251 . COrticosteroid in congenital adrenal hyperplasia (COCA). clinicaltrials.gov/show/NCT02552251 (first received 17 September 2015). ">COCA</a>; <a href="./references#CD012517-bbs2-0033" title="EUCTR2011‐005822‐23‐NO . A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐005822‐23‐NO (first received 25 February 2013). NCT01771328 . Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia. clinicaltrials.gov/show/nct01771328 (first received 18 January 2013). ">NCT01771328</a>; <a href="./references#CD012517-bbs2-0034" title="EUCTR2015‐000711‐40‐NL . Chronocort®, a slow release medicinal preparation of hydrocortisone, will be compared with currently used glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia seeking to assess its safety, tolerability and effectiveness. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015‐000711‐40‐NL (first received 17 November 2015). NCT02716818 . Comparison of chronocort® with standard glucocorticoid therapy in patients with congenital adrenal hyperplasia. clinicaltrials.gov/show/NCT02716818 (first received 23 March 2016). ">NCT02716818</a>; <a href="./references#CD012517-bbs2-0035" title="EUCTR2012‐001104‐37‐GB . Pulses study [Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia ‐ the pulses study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐001104‐37‐GB (first received 24 July 2014). ISRCTN67193733 . The Pulses Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN67193733 (first received 03 December 2014). ">PULSES</a>; <a href="./references#CD012517-bbs2-0036" title="NCT03532022 . Open‐label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE). clinicaltrials.gov/show/nct03532022 (first received 22 May 2018). ">RESTORE</a>). One trial plans to report androgen results such as testosterone and androstenedione (<a href="./references#CD012517-bbs2-0032" title="NCT02552251 . COrticosteroid in congenital adrenal hyperplasia (COCA). clinicaltrials.gov/show/NCT02552251 (first received 17 September 2015). ">COCA</a>). One trial plans to report on outcomes of QoL, fertility markers and hirsutism (<a href="./references#CD012517-bbs2-0036" title="NCT03532022 . Open‐label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE). clinicaltrials.gov/show/nct03532022 (first received 22 May 2018). ">RESTORE</a>). Three trials plan to report on plasma ACTH ( <a href="./references#CD012517-bbs2-0032" title="NCT02552251 . COrticosteroid in congenital adrenal hyperplasia (COCA). clinicaltrials.gov/show/NCT02552251 (first received 17 September 2015). ">COCA</a>; <a href="./references#CD012517-bbs2-0033" title="EUCTR2011‐005822‐23‐NO . A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐005822‐23‐NO (first received 25 February 2013). NCT01771328 . Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia. clinicaltrials.gov/show/nct01771328 (first received 18 January 2013). ">NCT01771328</a>; <a href="./references#CD012517-bbs2-0035" title="EUCTR2012‐001104‐37‐GB . Pulses study [Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia ‐ the pulses study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐001104‐37‐GB (first received 24 July 2014). ISRCTN67193733 . The Pulses Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN67193733 (first received 03 December 2014). ">PULSES</a>). Two trials plan to report bone markers such as P1NP and CTX (<a href="./references#CD012517-bbs2-0032" title="NCT02552251 . COrticosteroid in congenital adrenal hyperplasia (COCA). clinicaltrials.gov/show/NCT02552251 (first received 17 September 2015). ">COCA</a>; <a href="./references#CD012517-bbs2-0033" title="EUCTR2011‐005822‐23‐NO . A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐005822‐23‐NO (first received 25 February 2013). NCT01771328 . Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia. clinicaltrials.gov/show/nct01771328 (first received 18 January 2013). ">NCT01771328</a>) and one to report the change in DEXA scan (<a href="./references#CD012517-bbs2-0034" title="EUCTR2015‐000711‐40‐NL . Chronocort®, a slow release medicinal preparation of hydrocortisone, will be compared with currently used glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia seeking to assess its safety, tolerability and effectiveness. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015‐000711‐40‐NL (first received 17 November 2015). NCT02716818 . Comparison of chronocort® with standard glucocorticoid therapy in patients with congenital adrenal hyperplasia. clinicaltrials.gov/show/NCT02716818 (first received 23 March 2016). ">NCT02716818</a>). </p> <p>None of the trials plan to report our outcomes of the prevention of adrenal crisis, testicular or ovarian adrenal rest tumours. However, four trials plan to report outcomes not included in our review: three trials plan to report on lipid profile (<a href="./references#CD012517-bbs2-0031" title="NCT03760835 . Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME). clinicaltrials.gov/show/nct03760835 (first received 30 November 2018). ">CareOnTIME</a>; <a href="./references#CD012517-bbs2-0033" title="EUCTR2011‐005822‐23‐NO . A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐005822‐23‐NO (first received 25 February 2013). NCT01771328 . Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia. clinicaltrials.gov/show/nct01771328 (first received 18 January 2013). ">NCT01771328</a>; <a href="./references#CD012517-bbs2-0035" title="EUCTR2012‐001104‐37‐GB . Pulses study [Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia ‐ the pulses study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐001104‐37‐GB (first received 24 July 2014). ISRCTN67193733 . The Pulses Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN67193733 (first received 03 December 2014). ">PULSES</a>) and one on body weight (<a href="./references#CD012517-bbs2-0036" title="NCT03532022 . Open‐label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE). clinicaltrials.gov/show/nct03532022 (first received 22 May 2018). ">RESTORE</a>). </p> </section> </section> </section> </section> <section id="CD012517-sec-0083"> <h3 class="title">Risk of bias in included studies</h3> <p>We judged all trials as at unclear or high risk of bias in one or more 'Risk of bias' domains. These judgements are presented in a graph (<a href="#CD012517-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012517-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012517-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012517-sec-0084"> <h4 class="title">Allocation</h4> <section id="CD012517-sec-0085"> <h5 class="title">Sequence generation</h5> <p>All trials stated that allocation was randomised, but no trials described the method of randomisation used. We therefore judged the risk of bias due to the generation of the randomisation sequence as unclear in all trials (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> </section> <section id="CD012517-sec-0086"> <h5 class="title">Allocation concealment</h5> <p>Concealment of allocation was not reported in any trial in which the randomisation procedure was carried out and all trials were deemed as having an unclear risk of bias (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> </section> </section> <section id="CD012517-sec-0087"> <h4 class="title">Blinding</h4> <p>Only two trials reported double blinding resulting in low risk of bias (<a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). The remaining three trials did not report blinding of investigators or participants (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>). We considered the risk of bias to be high if this aspect of trial quality was not discussed because the intervention was clearly different, therefore the blinding could not take place for the participants or caregivers. </p> </section> <section id="CD012517-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>No trials explicitly stated that an intention‐to‐treat analysis was performed or whether any participants deviated from the randomised group to which they were assigned. One trial reported that four out of nine participants recruited subsequently withdrew due to difficulties maintaining peripheral IV access therefore the risk of bias was high (<a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>). The remaining four trials did not report attrition rates, therefore the risk of bias was also deemed as high (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> </section> <section id="CD012517-sec-0089"> <h4 class="title">Selective reporting</h4> <p>We were unable to identify any selective reporting in the included trials, but did not have any access to the original trial protocols to definitely confirm this. We did contact the lead investigators of two trials, but have not received a reply to date (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>). We therefore concluded that there is a high risk of bias due to selective reporting for all trials (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> </section> <section id="CD012517-sec-0090"> <h4 class="title">Other potential sources of bias</h4> <p>We were unable to identify any other potential sources of bias; but did not have any access to the original trial protocols to definitely confirm this. There was lack of information in all cross‐over trials with regards to lack of washout periods. We therefore concluded that there is an unclear risk from other potential sources of bias for all trials (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> </section> </section> <section id="CD012517-sec-0091"> <h3 class="title" id="CD012517-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD012517-tbl-0001"><b>Summary of findings for the main comparison</b> HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose for treating CAH</a>; <a href="./full#CD012517-tbl-0002"><b>Summary of findings 2</b> HC (15 mg/m²/day) versus PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) for treating CAH</a>; <a href="./full#CD012517-tbl-0003"><b>Summary of findings 3</b> HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day) for treating CAH</a>; <a href="./full#CD012517-tbl-0004"><b>Summary of findings 4</b> HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) for treating CAH</a> </p> <p>Due to the heterogeneity of the included trials and the limited amount of evidence on patient‐important outcomes, we were unable to perform any meta‐analyses. We were unable to group data into the time points we had originally planned and so report results from the end of each trial. The duration of each trial is detailed in the table <a href="./references#CD012517-sec-0130" title="">Characteristics of included studies</a>. </p> <p>The evidence grades stated for the outcomes reported in the summary of findings tables are based on GRADE (<a href="#CD012517-sec-0054">Data collection and analysis</a>) and further details are provided in the tables (<a href="./full#CD012517-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012517-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012517-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012517-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD012517-sec-0092"> <h4 class="title">Primary outcomes</h4> <section id="CD012517-sec-0093"> <h5 class="title">1. QoL score</h5> <p>This outcome was not reported in any of the trials.</p> </section> <section id="CD012517-sec-0094"> <h5 class="title">2. Androgen normalisation</h5> <p>All five reported on this outcome using different measurements. Five trials reported 17 OHP levels (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>), four trials reported androstenedione (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>), three trials reported testosterone (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>), and one trial reported DHEAS (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>). </p> <section id="CD012517-sec-0095"> <h6 class="title">HC (13.5 mg/m²/day vs 15.5 mg/m²/day: high morning HC dose versus high evening HC dose </h6> <p>Androgen normalisation (determined by biochemical parameters such as 17 OHP, androstenedione, testosterone and DHEAS) was not significantly different between groups after four weeks of treatment in one cross‐over trial (n = 15) (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>) (very low‐quality evidence). These results were presented as median (interquartile (IQR) range) and so could not be analysed within RevMan. </p> <p>Results for 17 OHP showed a median (IQR) 44.00 nmol/L (16.00 to 116.00) for the high morning HC dose group (n = 5) compared to 33.00 nmol/L (15.00 to 76.00) for the high evening HC dose group (n = 6). Androstenedione was reported as 1.80 nmol/L (1.0 to 3.0) in the high morning HC dose group compared to 1.90 nmol/L (1.20 to 6.50) in the high evening HC dose group. The median (IQR) testosterone was 0.70 nmol/L (0.30 to 2.30) in the high morning HC dose group compared to 1.1 nmol/L (0.60 to 2.70) high evening HC dose group. Finally, in the high morning HC dose group the median (IQR) DHEAS was 0.20 nmol/L (0.20 to 0.60) compared to 0.40 nmol/L (0.20 to 0.70) in the high evening HC dose group (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>). </p> </section> <section id="CD012517-sec-0096"> <h6 class="title">HC (15 mg/m²/day) versus PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day)</h6> <p>One trial (n = 27) compared HC 15 mg/m²/day in three doses (n = 9) to PD 3 mg/m²/day in two doses (n = 9) and to DXA 0.3 mg/m²/day in a daily single dose (n = 9) (<a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>) (very low‐quality evidence). After six weeks, DXA resulted in significantly lower levels of 17 OHP compared to HC (P &lt; 0.001) and compared to PD (P &lt; 0.001). Similarly, androstenedione levels were significantly lower with DXA when compared to HC (P = 0.016) and PD (P = 0.002). It was reported that HC and PD had similar adrenal hormone levels. Compared with PD, 17 OHP and androstenedione were suppressed more with HC and DXA treatment (<a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>) </p> </section> <section id="CD012517-sec-0097"> <h6 class="title">HC (12.5 mg/m²/day) with placebo at five different schedules</h6> <p>Winterer (n = 8) compared five different HC and placebo dosing regimens with a total dose of 12.5 mg/m²/day in a cross‐over design; duration varied from four to six weeks for each dosing schedule. Treatment or placebo were given in different combinations at three time‐points across the day (morning, noon, evening). Investigators reported no significant difference in 17 OHP between the different dosing schedules (<a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). </p> <p>As the results were presented graphically, we were not able to extract the data. The review authors have attempted to contact the trial authors to see if raw data are available. </p> </section> <section id="CD012517-sec-0098"> <h6 class="title">HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day)</h6> <p>Caldato compared three times‐daily HC to once‐daily PD for one year (n = 44) (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). In the analysis, we have presented the data split as was reported in the paper (prepubertal participants and pubertal participants) and report total data here. Final values of 17 OHP were not significantly different between groups at one year, MD 1189.10 nmol/L (95% CI ‐51.08 to 2429.28) (<a href="./references#CD012517-fig-0003" title="">Analysis 1.1</a>) (very low‐quality evidence). However, there were significantly higher levels of androstenedione in the HC group, MD 57.75 nmol/L (95% CI 11.19 to 104.31) (<a href="./references#CD012517-fig-0004" title="">Analysis 1.2</a>) (very low‐quality evidence). Levels of testosterone showed no difference between HC or PD groups, MD 38.55 nmol/L (95% CI ‐6.48 to 83.58) (<a href="./references#CD012517-fig-0005" title="">Analysis 1.3</a>) (very low‐quality evidence). </p> </section> <section id="CD012517-sec-0099"> <h6 class="title">HC (15 mg/m²/day) versus HC (25 mg/m²/day) with fludrocortisone 0.1 mg/day</h6> <p>Silva compared once daily HC (15 mg/m²/day ) with once daily (25 mg/m²/day) HC plus fludrocortisone for six months using a cross‐over design (n = 26) (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). Investigators reported the median (IQR) values separately for prepubertal and pubertal participants so we were not able to analyse the data in RevMan. </p> <p>Median (IQR) levels of 17 OHP were more suppressed in the prepubertal group, with HC 25 mg/m²/day, 11.5 nmol/L (0.6 to 819.9) compared to HC 15 mg/m²/day 113.7 nmol/L (0.5 to 1207) (P &lt; 0.05); however this was not true for the pubertal group, where levels in the HC 15 mg/m²/day group were lower than in the HC 25 mg/m²/day group, 91.7 nmol/L (6.8 to 453.0) versus 314.2 nmol/L (66.5 to 568.7). Likewise, androstenedione median (IQR) levels in prepubertal participants were more suppressed on HC 25 mg/m²/day, 1.6 nmol/L (0.1 to 31.8), compared to the HC 15 mg/m²/day group, 3.4 (0.5 to 40.2) (P &lt; 0.05), Again, this was reversed for the pubertal participants where levels were lower in the HC 15 mg/m²/day group, 11 nmol/L (6.1 to 41.9), compared to the HC 25 mg/m²/day group, 22.3 nmol/L (10.5 to 47.5). No differences were noted in testosterone levels after six months in either prepubertal participants, HC 15 mg/m²/day group 2.5 nmol/L (0.8 to 9.1) versus HC 25 mg/m²/day group 2.3 nmol/L (1.2 to 11.3), or in pubertal participants HC 15 mg/m²/day group 4.7 nmol/L (3.9 to 6.9) versus HC 25 mg/m²/day group 6.2 nmol/L (3.5 to 9.2) (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>) (very low‐quality evidence for all androgen normalisation results). </p> </section> </section> <section id="CD012517-sec-0100"> <h5 class="title">3. Prevention of adrenal crisis</h5> <p>This outcome was not reported in any of the trials.</p> </section> </section> <section id="CD012517-sec-0101"> <h4 class="title">Secondary outcomes</h4> <section id="CD012517-sec-0102"> <h5 class="title">1. Presence of osteopenia</h5> <p>This outcome was not reported in any of the trials.</p> </section> <section id="CD012517-sec-0103"> <h5 class="title">2. Presence of testicular or ovarian adrenal rest tumours</h5> <p>This outcome was not reported in any of the trials.</p> </section> <section id="CD012517-sec-0104"> <h5 class="title">3. Subfertility</h5> <p>This outcome was not reported in any of the trials.</p> </section> <section id="CD012517-sec-0105"> <h5 class="title">4. Final adult height</h5> <p>Final adult height was not reported in any of the trials. However, the results of change in the ratio of bone age (BA) to chronological age (CA) and height velocity can be taken as surrogate markers for effects on final adult height since under‐treatment and the resulting excess production of androgens causes accelerated growth, advanced skeletal maturation and early epiphyseal fusion leading to reduced final adult height (<a href="./references#CD012517-bbs2-0051" title="RiepeFG , SippellWG . Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21‐hydroxylase deficiency. Reviews in Endocrine and Metabolic Disorders2007;8(4):349–63. ">Riepe 2007</a>). Two trials reported data we can present for this outcome (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). </p> <section id="CD012517-sec-0106"> <h6 class="title">HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day)</h6> <p>One trial (n = 44) found that once daily PD treatment after one year of treatment could lead to better control of bone maturation compared to HC especially in prepubertal children (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). Height SDS BA was significantly better for the PD group compared to the HC group, MD ‐0.81 (95% CI ‐1.47 to ‐0.15) (<a href="./references#CD012517-fig-0006" title="">Analysis 1.4</a>). No significant difference was found in height SDS CA between both groups, MD ‐0.14 (95% CI ‐0.99 to 0.71) (<a href="./references#CD012517-fig-0007" title="">Analysis 1.5</a>). Caldato also found that the ratio of BA/CA was higher in the HC group compared to the PD group at one year but the difference between groups was not significant, MD 0.15 (95% CI ‐0.03 to 0.33) (<a href="./references#CD012517-fig-0008" title="">Analysis 1.6</a>). After one year, Caldato (n = 34) reported that the absolute change in the ratio of BA/CA was higher in the HC group (‐0.64 to 0.01) compared to the PD group (0.37 to 0.11) (P &lt; 0.02) (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). Growth velocity SDS was similar in both groups with small changes from baseline after one year in both groups, ‐0.4 in the PD group and 0.43 in the HC group and no statistical difference demonstrated, MD 0.26 (95% CI ‐0.82 to 1.34) (<a href="./references#CD012517-fig-0009" title="">Analysis 1.7</a>) (very low‐quality evidence). Final height (cm) also did not show any statistical difference between groups after one year, MD ‐0.17 cm (95% CI ‐0.87 to 0.52) (<a href="./references#CD012517-fig-0010" title="">Analysis 1.8</a>). </p> </section> <section id="CD012517-sec-0107"> <h6 class="title">HC (15 mg/m²/day) versus HC (25 mg/m²/day) with fludrocortisone 0.1 mg/day</h6> <p>Silva compared once daily HC (15 mg/m²/day) with plus fludrocortisone to once daily (25 mg/m²/day) HC plus fludrocortisone for six months in a cross‐over trial (n = 26) (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). </p> <p>Height velocity was significantly reduced (P = 0.03) in the higher dosing HC plus fludrocortisone regimen compared with the lower daily HC plus fludrocortisone regimen. Both the paper and our analysis reported a significantly greater increase in height for the 22 pre‐pubertal children while using 15 mg/m²/day as compared with 25 mg/m²/day, MD 0.34 (95% CI 0.27 to 0.41) (P &lt; 0.00001) (<a href="./references#CD012517-fig-0011" title="">Analysis 2.1</a>) (very low‐quality evidence). </p> <p>We were not able to analyse the remaining data presented in the paper in RevMan and report them directly from the paper here. At the end of the trial, no significant differences were noted between groups in mean (SE) incremental growth hormone levels between the HC 15 mg/m²/day group 9.6 µg/L (2.0) and the HC 25 mg/m²/day group 6.9 µg/L (3.0). Investigators reported mean (SE) IGF‐1 levels split by age group and found no difference between doses for any age group; under six years of age, HC 15 mg/m²/day group (n = 16) 93.1 µg/L (14.9) compared to HC 25 mg/m²/day group (n = 15) 118.2 µg/L (20.6); for six to 12 years, HC 15 mg/m²/day group (n = 8) 320.0 µg/L (39.9) compared to HC 25 mg/m²/day group (n = 8) 310.0 µg/L (36.8); and for over 12 years, HC 15 mg/m²/day group (n = 2) 265.0 µg/L (25.0) compared to HC 25 mg/m²/day group (n = 2) 270.0 µg/L (30.0) (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012517-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012517-sec-0108"></div> <p>The main goal in CAH therapy is to achieve physiological replacement of cortisol deficiency while suppressing adrenal androgen overproduction. The effectiveness of long‐term treatment is of major clinical relevance due to the high risk of effects from over treatment or under treatment. Outcomes such as final adult height have been disappointing and additional problems such as infertility and poor QoL are common (<a href="./references#CD012517-bbs2-0048" title="Joint LWPES/ESPE CAH Working Group. Consensus statement on 21‐hydroxylase deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Pediatric Endocrinology. Journal of Clinical Endocrinology and Metabolism2002;87(9):4048‐53. ">LWPES/ESPE 2002</a>; <a href="./references#CD012517-bbs2-0049" title="MarumudiE , KhadgawatR , SuranaV , ShabirI , JosephA , AmminiAC . Diagnosis and management of classical congenital adrenal hyperplasia. Steroids2013;78(8):741‐6. ">Marumudi 2013</a>). </p> <p>Several different glucocorticoid replacement regimens and dosing schedules have been used, but it remains a challenge to reproduce the physiological circadian rhythm and pulsatile secretion of cortisol. In children, HC has been the preferred glucocorticoid replacement therapy due to potential concerns of growth suppression associated with longer acting glucocorticoids. </p> <section id="CD012517-sec-0109"> <h3 class="title" id="CD012517-sec-0109">Summary of main results</h3> <p>There are five randomised controlled trials (n = 101) in both children and adults included in the review; four of these had a cross‐over design (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>) and one was of parallel design (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). </p> <p>None of the included trials reported on the review's primary outcomes of QoL or prevention of adrenal crisis. All trials reported on androgen normalisation using a range of measurements: five trials reported 17 OHP levels (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>; <a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>), three trials reported androstenedione (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>; <a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>;) two trials reported testosterone (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>), and one trial reported DHEAS (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>). </p> <p>There were no significant differences in 17 OHP, testosterone, androstenedione or DHEA between a high morning dose of HC or a high evening dose after four weeks (<a href="./references#CD012517-bbs2-0002" title="GermanA , SuraiyaS , Tenenbaum‐RakoverY , KorenI , PillarG , HochbergZ . Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. Journal of Clinical Endocrinology and Metabolism2008;93(12):4707‐10. [CENTRAL: 668871; CRS: 5500050000000559; PUBMED: 18782876] ">German 2008</a>). One trial found that HC and DXA treatment suppressed 17 OHP and androstenedione more than PD treatment after six weeks (<a href="./references#CD012517-bbs2-0003" title="NebesioTD , RenbargerJL , NabhanZM , RossSE , SlavenJE , LiL , et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology2016;2016:17. [CENTRAL: 1308802; CRS: 5500135000001835; PUBMED: 27688786] ">Nebesio 2016</a>). A further trial reported no significant difference in 17 OHP between the five different dosing schedules of HC at between four and six weeks (<a href="./references#CD012517-bbs2-0005" title="WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Annals of the New York Academy of Sciences1985;458:182‐92. [CRS: 5500135000001837; PUBMED: 3879121] WintererJ , ChrousosGP , LoriauxDL , CutlerGB . Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. Journal of Pediatrics1985;106(1):137‐42. [CENTRAL: 36478; CRS: 5500050000000555; PUBMED: 3871229] ">Winterer 1985</a>). The trial comparing HC and PD found no differences in the values of 17 OHP, androstenedione and testosterone at one year (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>). The trial of HC versus HC plus fludrocortisone found that at six months 17 OHP and androstenedione levels were more suppressed on HC alone but there were no differences noted in testosterone levels (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). </p> <p>With regards to the secondary outcomes, none of the included trials reported on the presence of osteopenia, of testicular or ovarian adrenal rest tumours or subfertility. While no trial reported final adult height two trials did report surrogate markers of height and growth (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004</a>; <a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). </p> <p>Caldato found that after one year of once‐daily PD treatment could lead to better control of bone maturation compared to HC especially in prepubertal children (<a href="./references#CD012517-bbs2-0001" title="CaldatoMC , FernandesVT , KaterCE . One‐year clinical evaluation of single morning dose prednisolone therapy for 21‐hydroxylase deficiency. Arquivos Brasileiros de Endocrinologia e Metabologia2004;48(5):705‐12. [CENTRAL: 527921; CRS: 5500135000001830; PUBMED: 15761542] ">Caldato 2004)</a>. Height SDS BA was significantly better for the PD group MD ‐0.81 (95% CI ‐1.47 to ‐0.15) (<a href="./references#CD012517-fig-0006" title="">Analysis 1.4</a>), but there was no significant difference between groups in height SDS CA, the ratio of BA/CA, growth velocity SDS or height (cm) at the end of the one‐year trial. </p> <p>The six‐month Silva trial compared once daily HC 15 mg/m²/day with once daily HC 25 mg/m²/day with fludrocortisone 0.1 mg/day and found that height velocity was significantly reduced with the higher dose of HC with fludrocortisone (<a href="./references#CD012517-bbs2-0004" title="SilvaIN , KaterCE , CunhaCF , VianaMB . Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood1997;77(3):214‐8. [CENTRAL: 145358; CRS: 5500135000001828; PUBMED: 9370898] ">Silva 1997</a>). Height z score was significantly higher with once‐daily HC 15 mg/m²/day than with once‐daily HC 25 mg/m²/day with fludrocortisone, MD 0.34 (95% CI 0.27 to 0.41) (<a href="./references#CD012517-fig-0011" title="">Analysis 2.1</a>). There were no differences noted in growth hormone or IGF1 levels. </p> </section> <section id="CD012517-sec-0110"> <h3 class="title" id="CD012517-sec-0110">Overall completeness and applicability of evidence</h3> <p>All the trials in this review were single‐centre with a variable duration of treatment ranging from four weeks to one year. It was unfortunate that there are no long‐term trials reporting outcomes beyond a trial duration of one year (six months for each treatment arm). </p> <p>The five included trials reported on few of the review outcomes and used a variety of units of measurement, meaning we were unable to combine data in a meta‐analysis. Although 17 OHP and androstenedione are frequently used to monitor treatment, there is a great amount of variability in the measurements which hampers the usefulness of these tests. No trials included QoL outcomes and most trials did not report adverse events or serious adverse events. While there were differences reported in some growth outcomes, there were no differences noted in growth hormone or IGF1 levels indicating that laboratory markers are unreliable and clinical follow‐up is the most efficient way to evaluate adequacy of HC replacement. Since no trial presented data for final adult height, we reported a number of surrogate markers for this outcome. </p> </section> <section id="CD012517-sec-0111"> <h3 class="title" id="CD012517-sec-0111">Quality of the evidence</h3> <p>All the trials we included were small and had methodological weaknesses. There is relatively little replication of trials, with a single, small trial for each comparison. This weak evidence base makes it impossible to draw firm conclusions with confidence. Limitations included methodological quality, variations in intervention implementation, and outcomes. </p> <p>This review addressed a diverse range treatment regimens with many trials at high or unclear risk of bias. Generally, the lack of methodological detail provided in the trial reports did not allow us to assess risk of bias across the trials, and led to many high or unclear 'Risk of bias' ratings across the various domains. In particular, details of the methods of random sequence generation, concealment of treatment allocation, and blinding of the outcome assessors were often not reported, and therefore, we could not accurately determine the risk of bias. While we judged only one trial to be at a low risk of selection bias, the remaining four had a high risk of selection bias. It was not clear ant trial whether there were attempts to blind outcome assessors; therefore, we judged an unclear risk of detection bias. Due to lack of access to trial registrations and protocols, or limited reporting of important review outcomes, or both, we judged none of the trials to be at a low risk of reporting bias. Overall the risk of bias was moderate to high. </p> <p>The number of trials assessing different glucocorticoid regimens varied as well as the trial durations and It was difficult to draw overall conclusions from any single trial. Three trials were of a cross‐over design and we did not have the appropriate information to conduct comprehensive meta‐analyses, but trial authors have been contacted for further information in order that a more complete analysis can be carried out. </p> <p>The evidence as assessed using GRADE, is very low quality for all outcomes assessed across all trials. This means that new, better quality research is highly likely to change the overall conclusions of this review. </p> </section> <section id="CD012517-sec-0112"> <h3 class="title" id="CD012517-sec-0112">Potential biases in the review process</h3> <p>We attempted to avoid bias by ensuring that we had identified all relevant trials through comprehensive systematic searching of the literature and contact with trial investigators to identify other trials both published and unpublished. We also attempted to contact all authors where the original publication did not provide sufficient data, and planned to incorporate that data into the review; unfortunately, we have not received any information to date. It was not possible to evaluate the overall possibility of publication bias as not all trials reported the same outcomes and overall the trials were too heterogeneous to combine. The GRADE approach assessments were made by two people, independently, and discrepancies resolved by discussion. Data extraction was completed independently by two authors without financial interest in the outcome. </p> </section> <section id="CD012517-sec-0113"> <h3 class="title" id="CD012517-sec-0113">Agreements and disagreements with other studies or reviews</h3> <p>Since this is the first review published on this topic, comparisons to previous published systematic reviews are not possible. Although there is no NICE guidance available for treating and managing CAH, there are international guidelines outlining principles of diagnosis and management of CAH, but they do not specify recommendations for treatment regimens (<a href="./references#CD012517-bbs2-0054" title="SpeiserPW , ArltW , AuchusRJ , BaskinLS , ConwayGS , MerkeDP , et al. Congenital adrenal hyperplasia due to steroid 21‐hydroxylase deficiency: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology Metabolism2018;103(11):4043‐88. [doi: 10.1210/jc.2018‐01865; PUBMED: 30272171] ">Speiser 2018</a>). These guidelines recommend treatment with HC, but do not give details on specific timings or dose regimens. A maintenance dose of HC is recommended for children and adolescents with CAH who are still growing; while in adults with CAH, daily HC or long‐acting glucocorticoids plus mineralocorticoids, or a combination, is recommended as clinically indicated (<a href="./references#CD012517-bbs2-0054" title="SpeiserPW , ArltW , AuchusRJ , BaskinLS , ConwayGS , MerkeDP , et al. Congenital adrenal hyperplasia due to steroid 21‐hydroxylase deficiency: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology Metabolism2018;103(11):4043‐88. [doi: 10.1210/jc.2018‐01865; PUBMED: 30272171] ">Speiser 2018</a>). </p> <p>We were not able to include any long‐term RCTs which measured growth, but maintaining normal growth in CAH is a challenge and long‐term follow‐up trials have shown that individuals fail to achieve their predicted final adult heights (<a href="./references#CD012517-bbs2-0016" title="MathewsGA , FaneBA , PasterskiVL , ConwayGS , BrookC , HinesM . Androgenic influences on neural asymmetry: Handedness and language lateralization in individuals with congenital adrenal hyperplasia. Psychoneuroendocrinology2004;29(6):810‐22. [CRS: 5500135000001836; PUBMED: 15110930] ">Mathews 2004</a>; <a href="./references#CD012517-bbs2-0017" title="MerkeDP , KeilMF , JonesJV , FieldsJ , HillS , CutlerGB . Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism2000;85(3):1114‐20. [CENTRAL: 276265; CRS: 5500050000000561; PUBMED: 10720048] ">Merke 2000</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012517-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012517-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012517-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 1 17 OHP." data-id="CD012517-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 1 17 OHP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 2 Androstenedione." data-id="CD012517-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 2 Androstenedione. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 3 Testosterone." data-id="CD012517-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 3 Testosterone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 4 Height SDS BA." data-id="CD012517-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 4 Height SDS BA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 5 Height SDS CA." data-id="CD012517-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 5 Height SDS CA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 6 Ratio BA/CA." data-id="CD012517-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 6 Ratio BA/CA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 7 Growth velocity SDS." data-id="CD012517-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 7 Growth velocity SDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 8 Height cm." data-id="CD012517-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day), Outcome 8 Height cm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012517-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/urn:x-wiley:14651858:media:CD012517:CD012517-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_t/tCD012517-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hydrocortisone (15 mg/m²/day) versus hydrocortisone (25 mg/m²/day), Outcome 1 Height z score." data-id="CD012517-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Hydrocortisone (15 mg/m²/day) versus hydrocortisone (25 mg/m²/day), Outcome 1 Height z score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/media/CDSR/CD012517/image_n/nCD012517-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012517-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose for treating CAH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HC (13.5 mg/m²/day to 15.5 mg/m²/day) high morning dose compared with high evening dose for treating CAH</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CAH </p> <p><b>Settings</b>: outpatients, tertiary centre </p> <p><b>Intervention</b>: HC (13.5 mg/m²/day to 15.5 mg/m²/day): 50% daily dose in the morning followed by 25% at noon and 25% in the evening </p> <p><b>Comparison</b>: HC (13.5 mg/m²/day to 15.5 mg/m²/day): 25% daily dose in the morning and 25% at noon followed by 50% in the evening </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>High evening dose</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>High morning dose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androgen normalisation</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>Results for 17 OHP are presented as medians (IQR); 44 (16 to 116) for the high morning dose compared to 33 (15 to 76) for the high evening dose. </p> <p><b>Androstenedione (nmol/L)</b> </p> <p>Results for androstenedione are presented as medians (IQR); 1.80 (1.0 to 3.0) for the high morning dose compared to 1.90 (1.20 to 6.50) for the high evening dose. </p> <p><b>Testosterone (nmol/L)</b> </p> <p>Results for testosterone are presented as medians (IQR); 0.70 (0.30 to 2.30) for the high morning dose compared to 1.1 (0.60 to 2.70) for the high evening dose. </p> <p><b>DHEAS (nmol/L)</b> </p> <p>Results for DHEAS are presented as medians (IQR); 0.20 (0.20 to 0.60) for the high morning dose compared to 0.40 (0.20 to 0.70) for the high evening dose. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevention of adrenal crisis</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of osteopenia</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of testicular or ovarian adrenal rest tumours</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subfertility</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Final adult height</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>17 OHP</b> : 17‐hydroxyprogesterone; <b>CAH</b> : congenital adrenal hyperplasia; <b>CI</b> : confidence interval; <b>DHEAS</b> : dehydroepiandrosterone sulphate; <b>HC</b> : hydrocortisone; <b>IQR</b> : interquartile range; <b>NA</b> : not applicable; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for high risk of bias due to incomplete outcome data and selective reporting.<br/> <sup>b</sup> Downgraded once due to potential risk of bias: unclear details related to methodological design.<br/> <sup>c</sup> Downgraded due to uncertainty: small sample size and wide IQR. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose for treating CAH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012517-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HC (15 mg/m²/day) versus PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) for treating CAH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HC (15 mg/m²/day) versus PD (3.0 mg/m²/day) versus DXA (0.3 mg/m²/day) for treating CAH</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CAH </p> <p><b>Settings</b>: outpatients, tertiary centre </p> <p><b>Intervention</b>: HC (15 mg/m²/day) or PD (3.0 mg/m²/day) or DXA (0.3 mg/m²/day) </p> <p><b>Comparison</b>: DXA (0.3 mg/m²/day) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>DXA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HC or PD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androgen normalisation</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c,d</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>There were lower levels of 17 OHP reported in the DXA group compared to HC (P &lt; 0.001) and compared to PD (P &lt; 0.001). </p> <p><b>Androstenedione (nmol/L)</b> </p> <p>Androstenedione levels were significantly lower with DXA when compared to HC (P = 0.016) and PD (P = 0.002). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevention of adrenal crisis</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of osteopenia</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of testicular or ovarian adrenal rest tumours</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subfertility</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final adult height</b> </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>17 OHP</b> : 17‐hydroxyprogesterone; <b>CAH</b> : congenital adrenal hyperplasia; <b>CI</b> : confidence interval; <b>DXA</b> : dexamethasone; <b>HC</b> : hydrocortisone; <b>NA</b> : not applicable; <b>PD</b> : prednisolone; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for high risk of bias due to incomplete outcome data and selective reporting.<br/> <sup>b</sup> Downgraded once due to risk of bias: unclear details related to methodological design.<br/> <sup>c</sup> Downgraded due to uncertainty: small sample size so P values should be interpreted with caution.<br/> <sup>d</sup> Downgraded once for lack of applicability as included study only includes children so results are not applicable to adults. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HC (15 mg/m²/day) versus PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) for treating CAH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012517-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day) for treating CAH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day) for treating CAH</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CAH </p> <p><b>Settings</b>: outpatients, tertiary centre </p> <p><b>Intervention</b>: HC (10 mg/m²/day to 15 mg/m²/day) </p> <p><b>Comparison</b>: PD (2.4 mg/m²/day to 3.5 mg/m²/day) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>PD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Androgen normalisation</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>The mean level of 17 OHP across the prepubertals and pubertals group in the control group was 1737.00 nmol/L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>The mean level of 17 OHP was <b>1189.10 nmol/L higher</b> (51.08 lower to 2429.28 higher) with HC. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>Data reported separately for pubertal and pre‐pubertal participants. Neither individual result was significant; for the pre‐pubertal participants, MD 1436.00 nmol/L (95% CI ‐127.38 to 2999.38) and for pubertal participants, MD 770.00 nmol/L (95% CI ‐1266.86 to 2806.86). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Androstenedione (nmol/L)</b> </p> <p>The mean level of androstenedione across the prepubertals and pubertals group in the control group was 126.00 nmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Androstenedione (nmol/L)</b> </p> <p>The mean level of androstenedione in the HC group was <b>57.75 nmol/L higher</b> (11.19 higher to 104.31 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androstenedione (nmol/L)</b> </p> <p>Data reported separately for pubertal and pre‐pubertal participants. Neither individual result was significant; for the pre‐pubertal participants, MD 63.00 nmol/L (95% CI ‐4.57 to 130.57) and for pubertal participants, MD 53.00 nmol/L (95% CI ‐11.25 to 117.25). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Testosterone (nmol/L)</b> </p> <p>The mean testosterone level across the prepubertals and pubertals group in the control group was 82.00 nmol/L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Testosterone (nmol/L)</b> </p> <p>The mean testosterone level in the hydrocortisone group was <b>38.55 nmol/L higher</b> (6.48 lower to 83.58 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Testosterone (nmol/L)</b> </p> <p>Data reported separately for pubertal and pre‐pubertal participants. Neither individual result was significant; for the pre‐pubertal participants, MD 35.00 nmol/L (95% CI ‐29.13 to 99.13) and for pubertal participants, MD 42.00 nmol/L (95% CI ‐21.24 to 105.24). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevention of adrenal crisis</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of osteopenia</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of testicular or ovarian adrenal rest tumours</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subfertility</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final adult height</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height velocity in the PD group was 1.12.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height velocity in the HC group was<br/> <b>0.26 higher</b> (0.82 lower to 1.34 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for height velocity which is a surrogate measure for final adult height.</p> <p>The ratio of bone age to chronological age (a further surrogate marker for final adult height) was also measured and results suggest no difference between the groups, MD 0.15 (95% CI ‐0.03 to 0.33). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>17 OHP</b> : 17‐hydroxyprogesterone; <b>CAH</b> : congenital adrenal hyperplasia; <b>CI</b> : confidence interval; <b>DXA</b> : dexamethasone; <b>HC</b> : hydrocortisone; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>PD</b> : prednisolone; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for high risk of bias due to incomplete outcome data and selective reporting.<br/> <sup>b</sup> Downgraded once due to risk of bias: unclear details related to methodological design.<br/> <sup>c</sup> Downgraded once due to imprecision: outcome was downgraded due to imprecision and uncertainty, very large CIs around the MD. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day) for treating CAH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012517-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) for treating CAH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HC (15 mg/m²/day) vsus HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) for treating CAH</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CAH </p> <p><b>Settings</b>: outpatients, tertiary centre </p> <p><b>Intervention</b>: HC (15 mg/m²/day) </p> <p><b>Comparison</b>: HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HC with fludrocortisone </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androgen normalisation</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 OHP (nmol/L)</b> </p> <p>Results presented as medians (IQR) and split for prepubertal and pubertal participants. For prepubertals, the levels of 17 OHP were higher in the HC 15 mg/m²/day group, 113.7 (0.5 to 1207) compared to 11.5 (0.6 to 819.9) in the HC 25 mg/m²/day group. For the pubertal group, the levels of 17 OHP were lower in the 15 mg/m²/day group, 91.7 (6.8 to 453.0) compared to 314.2 (66.5 to 568.7) in the HC 25 mg/m²/day group. </p> <p><b>Androstenedione (nmol/L)</b> </p> <p>Results show that for prepubertals androstenedione levels were higher in the HC 15 mg/m²/day group, 3.4 (0.5 to 40.2) compared to the HC 25 mg/m²/day group, 1.6 (0.1 to 31.8). For the pubertal group, androstenedione levels were lower in the HC 15 mg/m²/day group, 11 (6.1 to 41.9) compared to the HC 25 mg/m²/day group, 22.3 (10.5 to 47.5). </p> <p><b>Testosterone (nmol/L)</b> </p> <p>Results show that testosterone levels for prepubertals were higher in the HC 15 mg/m²/day group, 2.5 (0.8 to 9.1) compared to the HC 25 mg/m²/day group, 2.3 (1.2 to 11.3). For the pubertal group, the levels of testosterone were lower in the HC 15 mg/m²/day group, 4.7 (3.9 to 6.9) compared to the HC 25 mg/m²/day group, 6.2 (3.5 to 9.2). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevention of adrenal crisis</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of osteopenia</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of testicular or ovarian adrenal rest tumours</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subfertility</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final adult height</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in height velocity between the 2 groups was<br/> <b>0.34 higher</b> (0.27 higher to 0.41 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b,c</sup><br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for height velocity which is a surrogate measure for final adult height.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>17 OHP</b> : 17‐hydroxyprogesterone; <b>CAH</b> : congenital adrenal hyperplasia; <b>CI</b> : confidence interval; <b>HC</b> : hydrocortisone; <b>IQR</b> : interquartile range; <b>NA</b> : not applicable; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for high risk of bias due to incomplete outcome data and selective reporting.<br/> <sup>b</sup> Downgraded once due to potential risk of bias: unclear details related to methodological design.<br/> <sup>c</sup> Downgraded due to uncertainty: small sample size and wide IQR. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) for treating CAH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/full#CD012517-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012517-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 17 OHP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1189.10 [‐51.08, 2429.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 1 year (pre‐pubertals)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1436.0 [‐127.38, 2999.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 1 year (pubertals)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>770.0 [‐1266.86, 2806.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Androstenedione <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>57.75 [11.19, 104.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 1 year (pre‐pubertals)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>63.0 [‐4.57, 130.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 1 year (pubertals)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>53.0 [‐11.25, 117.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Testosterone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>38.55 [‐6.48, 83.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 1 year (pre‐pubertals)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>35.0 [‐29.13, 99.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 1 year (pubertals)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>42.0 [‐21.24, 105.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Height SDS BA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Height SDS CA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Ratio BA/CA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Growth velocity SDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Height cm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hydrocortisone (10 mg/m²/day to 15 mg/m²/day) versus prednisolone (2.4 mg/m²/day to 3.5 mg/m²/day)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012517-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hydrocortisone (15 mg/m²/day) versus hydrocortisone (25 mg/m²/day)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Height z score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hydrocortisone (15 mg/m²/day) versus hydrocortisone (25 mg/m²/day)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012517.pub2/references#CD012517-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012517.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012517-note-0014">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012517-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012517-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012517-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD012517-note-0003">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012517-note-0005">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012517\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012517\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012517\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012517\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012517\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012517.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012517.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012517.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012517.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012517.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725875828"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012517.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725875832"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012517.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e85ee2b959371',t:'MTc0MDcyNTg3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 